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Abstract  
The compartmentalized nature of eukaryotic cells requires the distribution of 
enzymes, metabolites, and cofactors among the organelles. This includes 
nicotinamide adenine dinucleotide (NAD), an essential coenzyme, precursor, and 
substrate to many cellular reactions. For instance, this dinucleotide is used by the 
NAD+-dependent deacetylase sirtuin2 (SIRT2). The cytosolic location of this protein 
is in apparent contradiction to the nuclear location of some of its targets. In this study, 
whether a hitherto unidentified nuclear SIRT2 isoform could account for nuclear 
SIRT2-mediated deacetylation was investigated. A novel human SIRT2 isoform 
(SIRT2 isoform 5) was identified and shown to reside in the nucleus. Strikingly, this 
protein did not exhibit deacetylase activity towards several known SIRT2 targets. 
However, it retained the ability to interact with p300 in a NAD+-dependent manner. 
These results suggest a non-catalytic function for SIRT2-isoform 5 in the nucleus of 
human cells.  
The distribution of NAD+-consuming enzymes in subcellular compartments 
highlights the necessity for the maintenance of the different NAD+ pools. 
Mitochondria contain a substantial amount of the total cellular NAD+. In yeast and 
plants, mitochondrial NAD+ transporters ensure the maintenance of that pool, 
whereas in mammals such a transporter could not be identified so far. To address this 
problem, the closest human homologs to the Arabidopsis thaliana NAD+ transporter 
NDT2 were expressed in human cells. None of them increased mitochondrial NAD+ 
availability, indicating they do not function as NAD+ carriers in humans. This finding 
argues for autonomous NAD biosynthesis in human mitochondria. Indeed, 
nicotinamide mononucleotide adenylyltransferase 3 (NMNAT3), an isoform of the 
enzyme that catalyzes the last step of NAD synthesis, was reported to be localized to 
the mitochondria. However, all previous studies were done with a recombinant 
protein, and the presence of the endogenous protein is still debated. This study 
conclusively demonstrates the presence of the endogenous NMNAT3 protein in 
human mitochondria, supporting the idea of autonomous biosynthesis within these 
organelles.  
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On the basis of the observation that the expression of plant and yeast NAD+ 
transporters in human cells strongly increased mitochondrial NAD+ content, the 
consequences of increased mitochondrial NAD+ availability were investigated. Stable 
expression of the plant NAD+ transporter NDT2 in HEK293 cells resulted in growth 
retardation as well as a metabolic shift from mitochondrial respiration to glycolysis, 
and conferred increased resistance towards cell death induced by NAD+-depletion. 
These results suggest that distribution of NAD+ between the cytosol and the 
mitochondria is a major determinant of the metabolic profile of human cells.  
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1. Introduction 
A tremendous amount of research activities in molecular biology focuses on 
understanding both the function, and the dynamic interplay of proteins in living 
systems. Among this highly diverse class of biological macromolecules, enzymes are 
of particular interest owing to their ability to lower the activation energy required for 
a reaction to take place. No matter how important enzymes are, most of them are not 
capable of catalyzing their dedicated reactions on their own, and require additional 
cofactors referred to as coenzymes. The identification of these coenzymes thus 
opened up new directions, and their characterization revealed fascinating features. In 
1906, roughly two centuries after the first description of enzymes, Arthur Harden and 
William Young identified, that besides enzymes, a low molecular weight compound 
was required for fermentation and alcohol production. In the late 1920’s, Hans von 
Euler-Chelpin isolated this coenzyme, determined that it was composed of a sugar, 
adenine, and phosphate, and later described its dinucleotide nature. Finally, Arthur 
Kornberg described the synthesis of this coenzyme, namely nicotinamide adenine 
dinucleotide (NAD) [1]. 
NAD is a dinucleotide consisting of two mononucleotides, nicotinamide 
mononucleotide (NMN) and adenosine monophosphate (AMP), joined by their 
phosphate groups (Figure 1). NAD exists in the oxidized (NAD+) and reduced 
(NADH) forms, which reflects its function as a major electron carrier in metabolic 
redox reactions. As such, it is involved in major metabolic pathways, including the 
tricarboxylic acid (TCA) cycle, β-oxidation of fatty acids, amino acid catabolism, and 
the urea cycle. Furthermore, the cleavage of NAD+ in nicotinamide and ADP-ribose 
is the basis for post-translational protein regulation through ADP ribosylation, and 
deacetylation, and contributes to signaling events such as calcium signaling pathways 
and acetylation of histones in chromatin. 
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Figure 1: Structure of NAD. Nicotinamide adenine dinucleotide (NAD) consists of two nucleotides 
joined by phosphate groups. The nucleotides contain different bases: nicotinamide and adenine, 
respectively (boxed).  
1.1 NAD and NADP as potent redox agents 
The convertibility of the two forms, NAD+ and NADH (Figure 2), is the cornerstone 
of the role of NAD as coenzyme to many catabolic reactions involving 
dehydrogenases. In these reversible reactions, NAD+ accepts two electrons and a 
proton to be converted to NADH. For example, catabolism of glucose starts with 
glycolysis and the conversion of glucose to pyruvate. Pyruvate is subsequently 
transferred to the mitochondria where it is converted to acetyl coenzyme A (acetyl-
CoA) and degraded during the TCA cycle. In glycolysis, oxidation of glyceraldehyde 
3-phosphate is a dehydrogenation reaction involving the transfer of the hydrogen to 
NAD+, thus reducing it to NADH. Similarly, the TCA cycle enzymes isocitrate 
dehydrogenase, α-ketoglutarate dehydrogenase, and malate dehydrogenase also 
reduce NAD+ to NADH. In turn, complex I catalyzes the transfer of electrons from 
NADH generated in the mitochondria to a flavin mononucleotide (FMN)-containing 
flavoprotein of complex I of the electron transport chain (ETC). The transfer of 
electrons from one complex of the ETC to another is accompanied by the formation 
of a chemical and electrical gradient of protons across the mitochondrial inner 
membrane. This gradient constitutes the driving force of ATP synthesis.  
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Next to the NAD+/NADH redox pair, their phosphorylated counterparts NADP+ and 
NADPH constitute another redox couple that is largely involved in metabolic redox 
reactions. While many enzymes can use either, the presence of two similar but 
distinct redox pairs, with comparable redox potentials indicates that the two pairs are 
dedicated to different functions. While NAD is mostly present in the oxidized form 
and involved in catabolism, NADP is predominantly present as NADPH in cells and 
serves as the electron donor for reductive biosynthesis. For example, cholesterol is 
synthesized from acetyl-CoA in several steps. Among these reactions, those catalyzed 
by HMG-CoA reductase, squalene synthase and squalene monooxygenase convert 
NADPH to NADP+. While oxidation and reduction of NAD is mainly involved in 
metabolic reactions, the NADP/NADPH couple fulfills a broader scope of functions. 
For example, oxidation of NADPH is required for the regeneration of reduced 
cytochrome P450 and glutathione involved in detoxification, and oxidative defense, 
respectively [2,3]. 
1.2 Signaling functions of NAD 
In the late 1930’s Otto Warburg characterized NAD as an electron carrier. This major 
discovery laid the ground for extensive research exploring this function, and for many 
years NAD was solely regarded as an electron carrier. However, the identification of 
NAD as the precursor to a new post-translation modification, namely poly-ADP-
ribosylation [4], opened up the NAD field to new perspectives and since then, much 
research has been focusing on signaling events that are dependent on NAD and its 
derivatives. Remarkably, derivatives of both NAD and NADP have been associated 
with signaling pathways. For example, nicotinic acid adenine dinucleotide phosphate 
(NAADP), resulting from the exchange of the nicotinamide of NADP with nicotinic 
acid is considered to be the most potent intracellular calcium-mobilizing agent [1]. 
NAD+ is also an important substrate for reversible post-translational modifications, as 
it serves as the ADP-ribose donor for ADP-ribosylation catalyzed by mono- and poly-
ADP-ribosyltransferases. Moreover, deacetylation can be carried out by a group of 
NAD+-dependent deacetylases known as sirtuins (Figure 2). 
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Figure 2: Metabolic and signaling conversions of NAD(P). (1) Nicotinamide adenine dinucleotide 
(NAD+) is reduced at position 4 of the nicotinamide ring to NADH by dehydrogenases using NAD+ 
as cofactor; (2) phosphorylated NAD+ (NADP+) is generated by phosphorylation at position C2’ of 
the adenosine moiety, a reaction catalyzed by NAD Kinase (NADK), ATP is the phosphate donor; 
(3) NADP is reduced at position 4 of the nicotinamide ring to NADPH by dehydrogenases using 
NADP+ as cofactor; (4) NADK phosphorylates NADH at position C2’ (NADPH); (5) nicotinic acid 
adenine dinucleotide phosphate (NAADP) is generated from NADP by cyclic ADP-ribose hydrolase 
1 (CD38) by exchange of the nicotinamide (Nam) with nicotinic acid (NA); (6) deacetylation by 
sirtuins (SIRTs) results in nicotinamide (Nam) and adenosine diphosphate-ribose (ADPr) acetylated 
at position C2” of the ribose formerly bound to Nam (2’ OAADPR); (7) signaling reactions catalyzed 
by mono-ADP-ribosyl transferases (MARTs), poly-ADP-ribosyl transferases (PARPs) or CD38 
cleave the glycosidic bond between Nam and ADPr; (8) CD38 can also generate cyclic ADPr 
(cADPr) by formation of a glycosidic bond between position C1” of the ribose formerly bound to 
Nam and position 1 of the adenine ring. Reductive hydrogen atoms highlighted in red; phosphate 
groups in green; hydroxyl group in blue and acetyl group in orange. 
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1.2.1 Poly-ADP-ribosylation. 
Catalyzed by a group of enzymes known as poly-ADP-ribosyl polymerases (PARPs), 
poly-ADP-ribosylation (PARylation) is a reversible post-translational modification 
consisting in the cleavage of NAD+ into nicotinamide and ADP-ribose, the ADP-
ribose being subsequently transferred onto an acceptor protein, including PARP itself. 
Following attachment of an ADP-ribose unit onto the protein acceptor site, this ADP-
ribose moiety serves in turn as the acceptor site for a subsequent ADP-ribose. By 
further elongation, polymers consist in either linear or branched structures of 
successive ADP-riboses linked by glycosidic bonds and varying in length (Figure 3). 
The negatively charged polymers will typically consist of 200 to 400 units of ADP-
ribose with a branching point occurring every 20 to 50 units [5]. While NAD+ 
concentration does not appear to play a major role in the activation of PARPs [6], the 
extent of PAR formation seems to depend on NAD+ availability [7,8].  
PARPs constitute a superfamily of 17 members sharing a conserved signature motif. 
Although the 17 members share some structural similarities, only a few members 
have been shown to catalyze PAR formation. Some other members can catalyze for 
example mono-ADP-ribosylation [9]. Owing to its abundance and activity, nuclear 
PARP1 is considered to be the major NAD+-consuming enzyme in cells and has been 
extensively studied, especially with regards to its role in DNA single strand break 
repair (SSBR) [10]. Indeed, PARP1 recognizes DNA damages and modifies histones 
H1 and H2B, rendering chromatin more accessible to the repair machinery. 
Furthermore, PAR formation triggers cell-signaling events communicating the 
occurrence and extent of the damage to the cell. Based on these signals, the cell 
decides on the strategy (repair or suicide) to adopt. Finally, PARP activation leads to 
the recruitment of SSBR or base excision repair (BER) factors to the site of damage 
[9]. 
The NAD+-consuming nature of PARP1, as well as its preference for auto-
modification, can be exploited as a tool to enable visualization of cellular NAD+ 
pools.  
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In this PAR Assisted Protein Localization AssaY approach (PARAPLAY), the 
catalytic domain of PARP1 is rendered constitutively active by deletion of the DNA 
binding domain and targeted to the compartment of interest. Whereas NAD+ cannot 
be visualized by immunodetection methods, PAR can, and thus the extent of PAR 
formation reflects NAD+ availability in any given organelle [11]. 
 
 
 
 
Figure 3: Poly-ADP-ribosylation catalyzed by PARP1. Poly-ADP-ribose polymerase 1 (PARP1) 
catalyzes the cleavage of oxidized nicotinamide adenine dinucleotide (NAD+) (boxed) into 
nicotinamide (Nam) and ADP-ribose (ADPr), and subsequently transfers the ADP-ribose moiety onto 
the acceptor protein. Upon initiation, the first ADPr unit is transferred onto the acceptor protein. 
Polymer elongation results from the formation of glycosidic bonds between the riboses of two 
consecutive ADPr units (n, a number of ADPr units). Polymer branching occurs in the same way 
every 20 to 50 ADPr units. As it is a reversible modification, PAR can also be degraded: poly-ADP-
ribose glycohydrolase (PARG) hydrolyzes the glycosidic bonds, except for the ester bond between 
the acceptor protein and the first ADPr unit, which is removed by terminal ADP-ribose 
glycohydrolase (TARG1). Nicotinamide: Nam; Adenine: orange; ribose: Rib; phosphate groups: P 
(adapted from [9]). 
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1.2.2 NAD+-dependent deacetylation by sirtuins 
Regulation of cellular processes through post-translational modifications is well 
known. Among these modifications, addition of the acetyl moiety of acetyl-CoA onto 
the ε-amino group of lysine residues is named acetylation and carried out by lysine 
acetyltransferases (KATs). Initially identified on histone tails, acetylation activates 
transcription by neutralizing the positive charge harbored by lysine residues. By 
doing so, the interaction between the negatively charged DNA backbone and histones 
is weakened, thereby resulting in euchromatin formation [12-14]. Moreover, 
acetylation also establishes binding sites for proteins harboring a bromodomain. 
These domains recognize acetylated lysines and contribute to processes such as 
transcription activation or repression, nucleosome rearrangement, and alteration of 
chromatin architecture [15,16]. Beyond histones, further investigations revealed that 
over 1700 non-histone proteins are also targets for acetylation, and that this 
modification regulates nearly all cellular processes [17].  
Owing to the crucial role of acetylation, control of the acetylation state of the target 
proteins is of major importance. Hence, proteins catalyzing the removal of acetyl 
groups, namely deacetylases (KDACs), are equally important as KATs. KDACs can 
be divided in two superfamilies. The “classical” KDACs require a bivalent metal ion 
and hydrolyze the acetyl group releasing the deacetylated lysine and acetate [18]. In 
contrast, NAD+-dependent deacetylases consume NAD+ as a cofactor and release the 
deacetylated lysine and acetylated ADP-ribose [19].  
The yeast silent information regulator 2 (Sir2p) was the first deacetylase identified to 
be NAD+-dependent [19] and was demonstrated to participate, among others, in the 
silencing of the mating type loci and Ku-dependent double-strand DNA break repair 
[20,21]. Furthermore, Sir2p regulates transcriptional silencing of ribosomal DNA 
(rDNA), suppressing extrachromosomal rDNA circles arising from homologous 
recombination. This role in particular is believed to promote longevity in yeast. In 
line with this hypothesis, extra copies of Sir2 increase yeast life span whereas 
deletion of Sir2 has the opposite effect [22,23].  
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Seven homologs to Sir2p, named sirtuins (SIRTs), have been identified in mammals 
(SIRT1-7) [24,25]. Expressed ubiquitously in all tissues, they vary in their sub-
cellular location and activity (Table 1). In spite of the fact that deacetylation activity 
has been reported for all SIRTs, the different members of the family favor different 
substrates. SIRT1, 2 and 3 have a strong deacetylase activity towards a wide variety 
of substrates, whereas SIRT 5 prefers the removal of malonyl and succinyl chains 
[26]. Recently, SIRT6 was found to cleave long-chain fatty acids, such as myristic 
acid, from lysine residues. Furthermore, the presence of free fatty acids appears to 
enhance the deacetylation activity of SIRT6 [27]. As for SIRT4 and SIRT7, the 
activities and substrates remain poorly understood. 
Structure and catalytic mechanism of sirtuins 
All sirtuins share a highly conserved catalytic domain, consisting of approximately 
275 amino acids, but vary with regard to the lengths of their N- and C- terminal parts 
[24,28]. The 3D structure of the catalytic domain is highly similar for all sirtuins, 
including SIRT2, the sirtuin of interest in this study (Figure 4A). The overall SIRT2 
structure consists of a large Rossman-fold domain, typical of NAD-binding enzymes, 
and a second smaller domain containing two modules: a zinc binding ribbon and a 
helical domain made of 3 or 4 α-helices [29,30]. The interface between the small 
domain and the large Rossman-fold domain forms a cleft where the target acetylated 
lysine and NAD+ insert. Deacetylation of the target happens in two phases. First, 
NAD+ is hydrolyzed and nicotinamide is released. Second, the acetyl moiety is 
transferred onto ADPr and the products, O-acetyl-ADPr (OAADPR) and the 
deacetylated lysine, are released. Entry of NAD+ into the catalytic domain is followed 
by a nucleophilic attack of the acetylated target on the C1’ of the nicotinamide ribose 
resulting in the formation of an alkylamidate intermediate. Next, the catalytic 
histidine activates the 2’OH, which in turn attacks the alkylamidate thus generating a 
cyclic intermediate. Finally, the cyclic intermediate is attacked by a water molecule, 
thus releasing the deacetylated target and 2’OAADPR or 3’OAADPR [31] (Figure 
4B).  
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 Figure 4: Structure and catalytic mechanism of SIRT2: A) Ribbon representation of the structure 
of the small domain and Rossman-fold of human sirtuin 2 (SIRT2) in complex with ADP-ribose 
(ADPr). The zinc ion (Zn2+) is represented as a purple sphere; α-helices (yellow) and β-sheets 
(orange) are numbered from N- to C-terminal. N-terminus, C-terminus and ADPr are indicated with 
arrows (Adapted from [32]). B) Reaction mechanism of SIRT2. (1): The acetylated protein 
substitutes the nicotinamide (Nam) moiety of oxidized nicotinamide adenine dinucleotide (NAD+) on 
C1’ of the ribose. (2): Attack by the catalytic histidine (His) leads to the formation of the cyclic 
intermediate. (3): Release of the deacetylated target and (4) either 2’- or 3’-O-acetyl-ADP-ribose. 
In contrast to the other deacetylases, the zinc ion does not directly participate in the 
catalysis but rather stabilizes the catalytic domain [33]. The involvement of sirtuins in 
a variety of important cellular processes underlines the necessity for a tight regulation 
of their activity. For example, regulation of transcription in response to external 
stimuli was reported for SIRT1. Following caloric restriction, binding of cyclic AMP 
(cAMP) response element binding (CREB) to the SIRT1 promoter increases its 
transcription. In turn, SIRT1 can take part in the adenosine monophosphate protein 
kinase (AMPK) pathway: as a consequence to lower energy levels, the increased 
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AMP concentration activates AMPK, which in turn phosphorylates cytosolic PGC1α 
thereby triggering the translocation of the latter to the nucleus.  
There, PGC1α can be activated by SIRT1-mediated deacetylation, and enhance 
transcription of genes implicated in the regulation of mitochondrial functions and 
mobilization of energy reserves. Upon refeeding of the cells, the carbohydrate 
response element binding protein (ChREBP) will bind to the SIRT1 promoter, 
thereby inhibiting its transcription [34-36]. Other regulatory mechanisms of sirtuin 
activity include post-translational modification (e.g. phosphorylation), complex 
formation with endogenous inhibitors (e.g. deleted in breast cancer 1 (DBC1)) and 
NAD+ availability (e.g. competition with PARP1) [37,38].  
Sirtuins: NAD+-dependent enzymes with different activities and 
localization 
Of the seven human sirtuins, SIRT1, SIRT6 and SIRT7 are localized to the nucleus 
(Table 1). SIRT1 is the most extensively studied member of the SIRT family and its 
deacetylase activity has been linked to many cellular processes and diseases. 
Generally, activation of SIRT1 is associated with repression of transcription in 
situations of energetic stress such as calorie restriction, and thus SIRT1 is considered 
to be a key player in metabolic homeostasis. SIRT1 can repress transcription of 
metabolic genes by directly deacetylating histone 1 lysine 26 (H1K26), histone 3 
lysine 9 (H3K9) and histone 4 lysine 16 (H4K16) [39]. By removing the ε-acetyl 
group from the residues, SIRT1 promotes formation of heterochromatin, which is 
little accessible to the transcription machinery (“silent chromatin”). Besides histones, 
SIRT1 can also deacetylate a number of transcription factors such as P300/CBP, 
PGC1α, FOXO1, NFκB, HIF1α, HIF2α, all of them being involved in metabolic 
regulation [40].  
Displaying a much weaker deacetylase activity, SIRT6 also has fewer targets than 
SIRT1. Involved in genomic DNA stability and repair, SIRT6 also has a role in 
metabolism. Consistent with these functions, SIRT6 knockout mice exhibit aging-like 
phenotypes and shorter lifespan [41].  
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Table 1: Functions and targets of sirtuins (Adapted from [42]) 
Sirtuin Localizationa Reaction Targetsb Pathways References 
SIRT1 Nucleus 
[Cytosol] 
Deacetylation Many, e.g. 
H3K9Ac, 
H4K16Ac, 
Hif1α, NFκB, 
PGC1α, 
FOXO1, LXR, 
p53, BMAL1, 
AceCS1, β-
catein, PTEN 
TAF168, Tip60 
Many, e.g. 
transcription 
regulation, 
gluconeogenesis, 
circadian rhythm, 
apoptosis 
[19,43-54] 
SIRT2 Cytosol 
[Nucleus] 
 
Deacetylation Several, e.g. 
p300, 
H4K16Ac, 
H3K56Ac, α-
tubulin, 
PEPCK1, 
FOXO1 
Several, e.g., 
transcription 
regulation, 
microtubule 
organization, cell 
cycle progression, 
gluconeogenesis 
[55-60]  
SIRT3 Mitochondria 
[Nucleus] 
 
Deacetylation Many, e.g. 
AceCS2, GDH, 
HMGCS2, 
IDH2, LCAD, 
VLCAD, 
MnSOD, OTC, 
SDH2 
Many, e.g. Krebs 
cycle, acetylCoA 
metabolism, fatty 
acid oxidation, 
ROS response, 
amino acid 
catabolism, urea 
cycle 
[47,61-73]  
SIRT4 Mitochondria Mono-ADP-
ribosylation 
Deacetylation 
Lipoamidase 
GDH, MCD, 
PDHE2 
Amino acid 
catabolism, fatty 
acid oxidation 
[74-76] 
SIRT5 Mitochondria 
[Cytosol] 
 
Deacetylation 
Demalonylation 
Desuccinylation 
Deglutarylation 
CPS1, SOD1 Urea cycle, fatty 
acid oxidation  
[26,77-79]  
SIRT6 Nucleus 
 
Deacetylation 
Demyristoylation 
Depalmitoylation 
Mono-ADP-
ribosylation 
H3K9Ac, 
H3K56Ac, 
CtIP, TNFα, 
PARP1 
Genomic stability, 
glucose 
homeostasis, cell 
signaling 
[80-86]  
SIRT7 Nucleolus 
[Nucleus] 
 
Deacetylation H3K18Ac, 
PAF53, NPM1, 
GABP-β1, p53 
(debated)  
rDNA 
transcription, 
mitochondrial 
homeostasis 
[87-91] 
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a Primary subcellular localization is given first, additionally described localization is given in brackets. 
b Abbreviations: α-tubulin, alpha-tubulin; AceCS1/2, acetyl-coenzyme A synthase1/2;Β-catein, beta-catein; 
BMAL1, brain and muscle ARNT-like 1; CPS1, carbamoylphosphate synthase 1; CtIP, DNA endonuclease 
RBBP8; FOXO1, forkhead box protein O1; GABP-β1, GA- binding protein subunit beta-1; GDH,glutamate; 
dehydrogenase; H3K9, histone 3 lysine 9; H3K18, histone 3 lysine 18; H3K56, histone 3 lysine 56; H4K16, 
histone 4 lysine 16; HIF1α, hypoxia inducible factor 1-alpha; HMGCS2, 3-hydroxy-3-methylglutaryl-
coenzyme A synthase 2; IDH2, isocitrate dehydrogenase 2; LCAD, long-chain acyl-coenzyme A 
dehydrogenase; LXR, liver X receptor; MCD, malonyl-coenzyme A decarboxylase; MnSOD, superoxide 
dismutase [Mn]; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; NPM1, nucleophosmin; 
OTC, ornithine carbamoyltransferase; P53, cellular tumor antigen P53; P300, histone acetyltransferase p300; 
PAF53, DNA-directed RNA polymerase I subunit RPA49; PARP1, poly-ADP-ribose polymerase 1; PDHE2, 
pyruvate dehydrogenase subunit E2; PEPCK1, phosphoenolpyruvate carboxykinase 1; PGC1α, peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha; PTEN, phosphatase and tensin homolog; SDH2, 
succinate dehydrogenase 2; SOD1, superoxide dismutase [Cu-Zn]; TAF168, RNA polymerase I-specific TBP-
associated factor 68 kDa; Tip60, histone acetyltransferase tip60; TNFα, tumor necrosis factor- alpha; VLCAD, 
very long-chain acyl-coenzyme A dehydrogenase. 
 
Enriched in the nucleolus, SIRT7 exhibits deacetylase activity towards a limited set 
of targets, which are primarily involved in ribosomal DNA transcription [88,92], 
stabilization of cancer cell phenotypes [87,93-95], and mitochondrial biogenesis and 
function [91]. 
Of the remaining sirtuins, SIRT3, SIRT4 and SIRT5 reside in mitochondria due to the 
presence of mitochondrial targeting sequences. Among these, SIRT3 is the only one 
possessing a strong deacetylase activity, and is actually considered to be the major 
(and possibly sole) mitochondrial deacetylase [96]. Given that approximately 50% of 
all mitochondrial proteins involved in metabolic pathways possess at least one 
acetylation site [97], SIRT3 appears to be a key regulator of mitochondrial 
metabolism. SIRT5 also has the ability to deacetylate, however, to a much lesser 
extent than SIRT3. So far, only carbamoyl-phosphate synthase 1 (CPS1), involved in 
ammonia detoxification through the urea cycle, is found to be a target of SIRT5 for 
deacetylation. Instead, SIRT5 displays demalonylase, desuccinylase, and 
deglutarylation activities regulating among others urea production, fatty acid 
oxidation, TCA cycle, and glycolysis [26,77-79]. SIRT4 was proposed to act as mono 
ADP ribosyltransferase inhibiting glutamate dehydrogenase (GDH) thereby blocking 
amino acid-induced insulin secretion [74], and recently, deacetylation and 
delipoylation activities were detected towards malonyl-CoA decarboxylase (MCD) 
and pyruvate dehydrogenase (PDH), respectively [75,76].  
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SIRT2 is predominantly localized to the cytosol where, among other functions, it acts 
as a regulator of microtubule-associated events through the deacetylation of α-tubulin 
[55]. Although the role of tubulin acetylation remains unclear, it is generally regarded 
as a stabilizing factor involved in the recruitment of kinesin-1 and dynein, two motor 
proteins moving along the microtubules [98,99]. In addition, SIRT2 also carries out 
the deacetylation of several other targets including H4K16, p300 and FOXO1 and 
plays a role in processes such as gluconeogenesis, adipogenesis, and chromatin 
compaction [38,40,100].  
Remarkably, several nuclear events also require the activity of SIRT2. During the 
G2/M transition, SIRT2 accumulates and associates with chromatin to globally 
deacetylate H4K16 thereby facilitating H4K20 methylation and subsequent chromatin 
compaction. Whereas accumulation of SIRT2 appears to play a major role in the early 
mitotic events, a decrease of SIRT2 is important for mitotic exit, as demonstrated by 
the fact that SIRT2 overexpression delays reentry in the cell cycle [56,101,102]. 
Furthermore, SIRT2 is involved in other nuclear reactions independent of the cell 
cycle such as the inactivation of the transcription factor P300 [58] or deacetylation of 
H3K56 involved in DNA repair [59]. 
Topological paradox of sirtuins 
As mentioned above, sirtuins are preferentially localized to specific compartments. 
However, the target proteins of some sirtuins are not confined to a single subcellular 
compartment, and sirtuins themselves can exhibit alternative localization. Little is 
known about the mechanisms and physiological relevance of these different cellular 
distributions. For example, the predominantly nuclear protein SIRT1 was also 
detected in the cytoplasm of myoblast cells. This shuttling event is regulated by the 
phosphoinositie 3-Kinase (PI3K) signal cascade, which controls the two nuclear 
localization signals (NLS) and two nuclear export signals (NES) by post-translational 
modifications [103,104]. Furthermore, SIRT1 was shown to deacetylate the cytosolic 
acetyl-CoA synthase 1 (AceCS1) [47].  
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Two of the mitochondrial sirtuins may also exhibit alternative localization: SIRT3 
has been reported in the nucleus whereas alternative splicing of SIRT5 leads to the 
alteration of the C-terminal end of isoform 1 resulting in its retention in the cytoplasm 
[105-107]. Nevertheless, to date, no substrates outside the mitochondria have been 
reported for SIRT3 and SIRT5. 
The question as to how SIRT2-mediated nuclear processes are regulated is critical 
due to the non-negligible number of nuclear targets. While the breakdown of the 
nuclear envelope is likely to explain how SIRT2 associates with nuclear targets 
during mitosis, it is still unclear how SIRT2 mediates nuclear events during the 
interphase. 
Prior to this work, four transcript variants of SIRT2 had been deposited in the 
GenBANKa database. Analysis of the primary structure of SIRT2 isoforms 1 and 2, 
which differ by the use of an alternative start codon, revealed the presence of a 
chromosome region maintenance 1 protein homolog (CRM1)-dependent nuclear 
export signal encoded by exon 4 [108] (Figure 5). However, no nuclear import signal 
has so far been identified thus suggesting a passive import of SIRT2 and raising the 
question as to how SIRT2-mediated nuclear processes are regulated. 
 
 
 
 
Figure 5: Primary structure of SIRT2 isoforms 1 and 2. Isoforms 1 and 2 differ by the usage of an 
alternative start codon located at the junction between exons 3 and 4 resulting in a protein lacking the 
first 37 amino acids. The SIRT2 catalytic domain is indicated in blue, the N- terminal and C-terminal 
flanking regions are in grey and the nuclear export signal is in green. Black bars represent residues 
involved in substrate binding whereas white bars represent zinc-coordinating residues. Exon 
junctions corresponding to the primary structure are indicated by dotted lines. 
                                            
a GenBank accession numbers for the SIRT2 transcript variants (TV): TV1: NM_012237.3; TV2: NM_030593.2; TV3 
NM_001193286.1; TV4. NR034146.1. Experimental evidence is missing for isoforms 3 and 4 and thus, they will not be 
addressed 
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1.3 NAD biosynthetic pathways and enzymes 
As opposed to redox reactions, utilization of NAD+ as a signaling molecule leads to a 
net consumption of the dinucleotide. Consequently, perpetual biosynthesis of NAD+ 
is required to maintain physiological cellular concentrations (~300 μM) [109,110]. 
Several routes can lead to the synthesis of NAD, differing by the nature of the 
precursor used. Irrespective of which route is favored (e.g., depending on the 
organism), the first step of NAD biosynthesis is always the generation of a 
mononucleotide (Figure 6). 
De novo synthesis of NAD relies on the degradation of an amino acid precursor that 
can be aspartate in plants and bacteria or tryptophan in humans. Tryptophan, an 
essential amino acid, is mainly catabolized by the kynurenine pathway leading to 
quinolinic acid (QA), the substrate for quinolinic acid phosphoribosyl transferase 
(QAPRT). QAPRT yields nicotinic acid mononucleotide (NAMN) by catalyzing the 
decarboxylation and phosphoribosylation of QA using phosphoribosyl pyrophosphate 
(PRPP) as a co-substrate [111,112]. 
The relatively low contribution of de novo synthesis to NAD generation underlines 
the importance of the alternative biosynthetic route, the salvage pathway. As opposed 
to the de novo synthesis, the salvage pathway relies on recycling of the cleaved 
nicotinamide (Nam) moiety originating from NAD+-degrading activities such as 
PARylation and deacetylation performed by sirtuins. The resulting free Nam can be 
NMN by the rate-limiting enzyme nicotinamide phosphorybosyl transferase 
(NamPRT), which transfers the phosphoribosyl unit from PRPP onto Nam. 
Alternatively, the acid form of Nam, namely nicotinic acid (NA) may also serve as 
precursor in a biosynthetic route known as the Preiss-Handler pathway [113,114]. In 
this route, NA is converted to nicotinic acid mononucleotide (NAMN) by addition of 
phosphoribose provided by PRPP, a reaction catalyzed by nicotinic acid 
phosphoribosyl transferase (NAPRT). Interestingly, some organisms such as flies and 
worms do not display QAPRT activity, showing that the de novo pathway is not 
absolutely required for NAD synthesis [115].  
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Furthermore, it was shown for yeast that de novo synthesis contributes to a very small 
extent to NAD synthesis as long as the salvage pathways are functional [116], 
whereas QAPRT knock-out mice are viable provided a nicotinic acid diet [117]. 
In addition to QA, NA and Nam, two additional precursors were more recently 
discovered: the riboside forms of NA and NAM, nicotinic acid riboside (NAR) and 
nicotinamide riboside, respectively [118,119]. The riboside forms of NA and Nam are 
phosphorylated to NAMN and NMN, respectively, by nicotinamide ribose kinases 
(NRKs), where ATP serves as the phosphate donor. Alternatively, NR can be 
cleaved, liberating Nam that can in turn enter the salvage pathways [120-123].  
After generation of the mononucleotide, the second step of NAD synthesis is the 
reversible condensation of the adenylyl moiety from ATP with the mononucleotide 
(generated either from NA, NAR, Nam, QA or NR), a reaction accompanied by the 
release of pyrophosphate. Well conserved among species, this reaction is catalyzed 
by nicotinic acid/nicotinamide mononucleotide adenylyltransferases (NMNATs), the 
final product being either nicotinic acid adenine dinucleotide (NAAD) or NAD. 
When the biosynthetic pathway originates from the acidic mononucleotide, an 
additional step is required for the amidation of NAAD to NAD. This reaction is 
catalyzed by NAD synthase (NADS), and is dependent on glutamine as an ammonia 
donor in eukaryotes. 
Humans express three different NMNATs, which differ by their sub-cellular 
localization. NMNAT1 is the predominant isoform with regards to both activity, and 
tissue distribution. It is found in the nucleus [124] where it is involved in many NAD-
dependent nuclear processes. For example, PARP1 localized at target gene promoters 
recruits and interacts with NMNAT1 to regulate its activity by enhancing local NAD+ 
availability [125,126]. Similar observations have been made for the other major 
nuclear NAD+- consuming enzyme, namely SIRT1 [127]. NMNAT2 is localized to 
the Golgi apparatus and axonal vesicles [124,128,129], whereas overexpressed 
NMNAT3 reportedly co-localizes with mitochondrial structures [8,124] (Figure 6). 
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1.4 Compartmentalization of NAD+: biosynthesis and 
importance of the mitochondrial pool.  
The membranes in eukaryotic cells constitute impermeable barriers thereby creating 
distinct environments. This compartmentalized character allows for tremendous 
possibilities for regulation (e.g. by the spatial separation of anabolic and catabolic 
pathways). Control of pathways at this level requires metabolites, enzymes, and 
cofactors to cross the physical barrier that membranes are, a process often depending 
on proteins dedicated to the transport across membranes. The mechanisms underlying 
the cellular distribution of metabolites and cofactors are still the center of attention 
for many research groups. For example, although much was already known about the 
role of pyruvate in metabolism, it was only recently that a mitochondrial pyruvate 
carrier was identified [130,131]. 
The variety of reactions involving NAD highlights the central position of this 
coenzyme in cellular functions and the requirement for tight regulatory mechanisms. 
The compartmentalization of the eukaryotic cell provides an additional level of 
regulation by segregating NAD+-dependent enzymes as well as biosynthetic enzymes 
to specific compartments. 
In accordance with the wide cellular distribution of NAD+-dependent enzymes and 
processes, it is not surprising that NAD+ was also found to be distributed in several 
subcellular pools. A large proportion of NAD-dependent events takes place in the 
cytosol and nucleus and, although experimental evidence is still missing, it is 
generally believed that NAD+ can freely diffuse through the nuclear pores and thus, 
that these two pools are interchangeable and of equal concentration. Beside the 
nucleo-cytoplasmic pool, NAD+ was detected in the peroxisomes, Golgi, endoplasmic 
reticulum, and mitochondria [11], which may contain up to 70% of the total cellular 
NAD pool where it plays a vital role in multiple redox and signaling reactions [132].  
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Figure 6: Subcellular localization and reactions of the different NAD biosynthetic enzymes. The 
different entry points use extracellular precursors containing the pyridine moiety or tryptophan (Trp) 
as a precursor to quinolinic acid (QA). QA and nicotinic acid (NA) are converted to nicotinic acid 
mononucleotide (NAMN) by their respective phosphoribosyl transferase QAPRT and NAPRT. 
Nicotinamide phosphoribosyl transferase (NamPRT) catalyzes the conversion of nicotinamide (Nam) 
to nicotinamide mononucleotide (NMN). The riboside forms of Nam and NA, nicotinamide riboside 
[86] and nicotinic acid riboside (NAR), respectively, may also serve as precursors for NMN and 
NAMN. These reactions are catalyzed by nicotinamide riboside kinases (NRKs). Nicotinamide 
mononucleotide adenylyltransferases (NMNATs) catalyze the formation of nicotinamide/ nicotinic 
acid adenine dinucleotide (N(A)AD) and localize to the nucleus (NMNAT1, green), the Golgi 
apparatus (NMNAT2, yellow) or the mitochondria (NMNAT3, blue). NAD synthase (NADS) 
converts NAAD to NAD. The hypothetical import of NMN into mitochondria is represented by the 
dotted line.  
Owing to the importance of mitochondria in metabolic reactions and the role played 
by NAD+ in these reactions, several studies have recently highlighted the crucial role 
of mitochondrial NAD+ maintenance. For example, genotoxic stress resulting in the 
activation of PARP1 leads to severe cellular NAD+ depletion. However, 
mitochondrial NAD+ concentrations are maintained and promote cell survival, an 
effect depending on SIRT3 and SIRT4 [109].  
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Similarly, incubation of cells with the NamPRT inhibitor FK866 depletes cytosolic 
NAD+ whereas the mitochondrial NAD+ pool remains unaffected [133]. 
Conversely, consumption of mitochondrial NAD+ was demonstrated to affect 
mitochondrial respiration, lactate production and mitochondrial membrane potential 
[134]. Reduction of mitochondrial NAD+ availability may even lead to cell death: 
upon activation of the mitochondrial permeability transition pore, depletion of 
mitochondrial NAD+ and subsequent degradation by NAD+ catabolic enzymes can 
result in the loss of cellular metabolic integrity and potentially cell death [135]. 
Whereas much is known about NAD+-dependent processes in the mitochondria, 
information regarding establishment and maintenance of the mitochondrial NAD+ 
pool is rather scarce. Two possible mechanisms may explain how mitochondrial 
NAD+ is brought about. On the one hand, a dedicated carrier could directly import 
NAD+. An alternative to direct import is intra-organellar biosynthesis. In 
Saccharomyces cerevisiae and Arabidopsis thaliana, ScNDT1 and AtNDT2, 
respectively, were identified as membrane carriers mediating NAD+ transport across 
the inner mitochondrial membrane [136,137]. In contrast to yeast and plants, the only 
human NAD+ carrier identified is SLC25A17 [138], which mediates the transport of 
NAD+ across the peroxisomal membrane, and to date, no mitochondrial NAD+ 
transporter has been identified in humans or other mammals [74,109,139].  
While all the other biosynthetic enzymes are localized to the nucleus and cytoplasm, 
the suggested presence of NMNAT3 within the mitochondria implies that generation 
of mitochondrial NAD+ may rely on the import of NMN and subsequent conversion 
of the mononucleotide to NAD+. Nevertheless, the hypothesis of mitochondrial NAD 
biosynthesis is debated, mostly due to the lack of experimental evidence for the 
presence of the endogenous NMNAT3 protein. Several studies have indicated the 
presence of the mRNA whereas the overexpressed protein has been detected in 
mitochondria [8,124,140-142]. Nevertheless, conclusive evidence for the protein 
within mitochondria is still missing.   
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Therefore, given the uncertainties regarding the presence of NMNAT3 in 
mitochondria of human cells, it has remained an open question whether there is an 
autonomous biosynthesis of NAD within these organelles. 
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2. Aims of the study 
In the light of the compartmentalization of human cells, it is obvious that complex 
mechanisms must regulate not only the activity of NAD metabolic enzymes, but also 
the distribution of these enzymes and of NAD+ itself. Thus, understanding the 
mechanisms underlying these events is of critical importance and provided the basis 
to the scientific problems addressed in this dissertation.  
The ability of SIRT2 to deacetylate nuclear targets is an apparent contradiction to its 
predominantly cytosolic location. One major aim was to provide further insights into 
the regulatory mechanisms involved in nuclear deacetylation by SIRT2. Sirtuins may 
exhibit alternative localization due to alternative splicing, and the recent 
identification of a new SIRT2 splice variant in mice, lacking the nuclear export signal 
and thus localized to the nucleus, shed new light on the topic of SIRT2 localization. 
Whether such an isoform existed in human remained to be elucidated. The objective 
of this part of the study was therefore to establish if a nuclear splice variant of SIRT2 
existed and if it could account for nuclear deacetylation. 
Owing to the major importance and observed segregated nature of mitochondrial 
NAD+, modulations of that pool may result in dramatic changes in cellular processes 
such as metabolic pathways. In accordance with this, it has been previously reported 
that the decrease of mitochondrial NAD+ availability affects metabolism, lactate 
production, and mitochondrial membrane potential. A second aim of this study was 
thus to analyze the consequences arising from the subcellular redistribution of NAD+. 
More specifically, the intent was to increase mitochondrial NAD+ availability and 
assess the cellular response to this change, especially with regards to metabolic 
functions.  
Another challenge arising from the isolation of the mitochondrial NAD+ pool lies in 
its establishment. Whereas mitochondrial NAD+ carriers have been characterized in 
yeast and Arabidopsis thaliana, no human homolog has so far been identified.  
 22
The localization of an NMNAT isoform (NMNAT3) to the mitochondria suggests 
that mitochondrial NAD+ is synthesized within these organelles. However, 
experimental proof of the endogenous protein is still missing. Another goal of this 
study was thus to address the question of whether a NAD+ carrier exists for human 
mitochondria, or if NAD+ is synthesized within these organelles.  
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3. Summary of the results 
3.1 Constitutive nuclear localization of an alternatively 
spliced Sirtuin2 protein isoform 
Paper I investigated the possibility that a not yet identified nuclear isoform of the 
SIRT2 protein may be responsible for deacetylation of SIRT2 nuclear targets. PCR 
analyses performed on cDNA from several human cell lines led to the identification 
of a new SIRT2 transcript variant linking exon 1 to exon 5. Given that SIRT2 protein 
isoforms 1, 2, 3 and 4 were already deposited in the GenBank database, the new 
isoform was named isoform 5. Compared to SIRT2 isoform 1, this new isoform is 
characterized by the substitution of amino acids 6 to 76 by an arginine residue. The 
alternative splicing of SIRT2 leads to the exclusion of the NES encoded by exon 4 in 
SIRT2 isoform 1. Expression of the open reading frame of SIRT2 isoform 5 in the 
context of its endogenous 5’UTR resulted in a protein product of expected size. The 
absence of the NES suggested that this isoform could be localized to a different sub-
cellular compartment than the cytosol. Immunocytochemistry as well as western blot 
analysis following cell fractionation determined that SIRT2 isoform 5 is indeed 
predominantly localized to the nucleus. To investigate the possibility that SIRT2 
isoform 5 accounts for nuclear deacetylation events carried out by SIRT2, its activity 
towards several acetylated targets was assessed both by in vitro and in vivo 
approaches. Surprisingly, isoform 5 failed to deacetylate all targets tested (HAT 
domain of P300, chemically acetylated histones and α-tubulin). A possible reason for 
this could be that, due to the splicing event, the catalytic domain of SIRT2 isoform 5 
is slightly truncated, and α-helix α1 of the Rossman-fold is missing. Molecular 
modeling analysis with homology modeling and threading suggested that, in spite of 
the changes in the catalytic domain, SIRT2 isoform 5 adopts a fold similar to that of 
isoforms 1 and 2, which was further confirmed by protein denaturation and intrinsic 
tryptophan fluorescence shift assay. Finally, although unable to deacetylate it, SIRT2 
isoform 5 retained the ability to interact with P300, which may suggest a non-
catalytic function for this isoform.  
 24
3.2 Subcellular distribution of NAD+ between cytosol and 
mitochondria determines the metabolic profile of 
human cells 
It was previously shown that a diminished mitochondrial NAD+ pool affects 
mitochondrial metabolism. Paper II aimed at understanding the impact of increased 
mitochondrial NAD+ availability and the consequences of the redistribution of NAD+ 
between the cytosol and the mitochondria. Mitochondrial NAD+ availability was 
successfully increased by expressing mitochondrial NAD+ transporters from yeast or 
plants (ScNDT1 and AtNDT2 respectively) but overexpression of the closest human 
homologs (SLC25A32, SLC25A33 and SLC25A36) failed to do so. A cell line stably 
expressing AtNDT2 (293AtNDT2) was established, and the elevation of 
mitochondrial NAD+ availability in these cells was confirmed. The redistribution of 
cellular NAD+ had several physiological consequences for the cells. 293AtNDT2 cells 
proliferated at a slower rate compared to the control cells, a phenotype that could not 
be rescued by addition of nicotinic acid, indicating that the slow growth did not result 
from impaired total NAD+ availability. Incubation with NamPRT inhibitor FK866 
revealed that the 293AtNDT2 cells were less sensitive towards NAD biosynthesis 
inhibition. It has been previously reported that consumption of mitochondrial NAD+ 
reduced mitochondrial respiration and increased lactate production with accelerated 
acidification of the cell culture medium [134]. Surprisingly, the stable expression of 
AtNDT2 also resulted in increased lactate production accompanied by a drop of pH of 
the cell culture medium. To further understand the metabolic consequences of 
increased mitochondrial NAD+ availability, mitochondrial respiration and glycolytic 
function were assessed using a SeaHorse XF analyzer. Redistribution of NAD+ from 
the cytosol to the mitochondria led to a metabolic shift from respiration to glycolysis. 
The dramatic phenotypes displayed by 293AtNDT2 cells indicate that the presence of 
such a transporter in human mitochondria might be harmful and that intra-organellar 
NAD biosynthesis is likely to be the source for mitochondrial NAD+. This hypothesis 
was substantiated by western blot analysis providing evidence for the existence of 
endogenous NMNAT3 protein in human mitochondria.  
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4. General Discussion 
NAD holds a central position in cells due to its involvement not only in metabolic 
redox reactions, but also in major signaling events including PARylation, Sirtuin-
mediated deacetylation, and calcium signaling. As such, this co-substrate influences 
virtually every cellular function, and understanding of NAD+-dependent processes is 
of vital importance. In the present study, key questions relative to NAD+ metabolism 
and distribution, in the frame of subcellular compartmentalization, were addressed.  
Compartmentalization of eukaryotic cells provides an additional level of regulation. 
Indeed the confinement of enzymes to specific locations, as well as the maintenance 
of different concentrations of cofactors results in local environments influencing the 
functions of these compartments. However, the membranes constitute obstacles to the 
free distribution of biomolecules thus raising several questions as to how the 
distribution of enzymes and cofactors is regulated.  
4.1 Compartmentation of NAD metabolic enzymes  
4.1.1 The nuclear isoform of SIRT2 does not deacetylate nuclear 
targets 
The first aspect of this study consisted in investigating the topological paradox of 
SIRT2 activity. As mentioned in the previous sections, SIRT2 mainly resides in the 
cytosol, but is able to deacetylate a considerable number of nuclear targets and 
participates in the control of, among others, cell division and transcriptional events 
(Table 1). Whereas the rupture of the nuclear envelope can explain the interaction 
between SIRT2 and nuclear partners during mitosis, how deacetylation of nuclear 
proteins during the interphase is regulated remains poorly understood. A previous 
study has identified a CRM1-dependent NES, but no functional NLS has so far been 
identified in SIRT2. The authors thus suggested that nuclear import of SIRT2 
happens passively by a “piggy-back” mechanism [108].  
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However, nuclear deacetylation events mediated by SIRT2 ought to be tightly 
regulated. Thus, it is unlikely that the regulation of these deacetylation events 
depends on passive nuclear import of SIRT2. 
In paper I, analysis of cDNA from several human cell lines revealed the existence of 
a new splice variant and confirmed the previously reported data from mice [143,144]. 
This new isoform, named SIRT2 isoform 5, results in an “in frame” mRNA excluding 
exons 2 to 4. Owing to the splicing event, isoform 5 lacks the NES present in SIRT2 
isoforms 1 and 2 [108] and predominantly resides in the nucleus. Furthermore, 
computational NLS prediction indicated the presence of a candidate weak bipartite 
non-canonical NLS in the C-terminal region of SIRT2 (residues 342-375 in isoform 
1). 
The particular localization of isoform 5 suggested that it could be responsible for 
SIRT2-mediated deacetylation occurring in the nucleus. As outlined by several 
experimental approaches in Paper I, SIRT2 isoform 5 surprisingly failed to 
deacetylate any of the reported targets tested. In order to determine whether the lack 
of activity was the result of structural impairments, further attention was given to the 
structural features of isoform 5. Beyond the deletion of the NES, 12 residues from the 
conserved catalytic domain are also absent in SIRT2 isoform 5. Importantly, all 
amino acids reported as essential for SIRT2 activity are still present in isoform 5 
[32,145]. The data presented in this paper further indicate that the removal of this 
stretch of residues is unlikely to affect the overall structure of SIRT2. In fact, all three 
isoforms tested (isoforms 1, 2 and 5) displayed very similar denaturation profiles. 
Furthermore threading and homology modeling predicted a structure resembling that 
of isoforms 1 and 2 for SIRT2 isoform 5. In spite of these similarities, the Rossman-
fold of isoform 5 could still be affected by the absence of α-helix 1. This is however 
unlikely given the remote position of this helix compared to the catalytic pocket. In 
line with this, the bacterial sirtuin CobB was also shown to lack the corresponding 
helix but remained an active sirtuin [146]. Interestingly, SIRT2 isoform 5 retained the 
ability to associate with P300, a known target of SIRT2 [58,147].  
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The strength of this interaction appears to be dependent on the concentration of 
NAD+ indicating that both substrate binding and NAD+ binding pockets remain intact. 
Thus, the apparent inactivity of SIRT2 isoform 5 may result from very subtle changes 
in the overall structure of this isoform.  
Although the results presented in this study indicate that SIRT2 isoform 5 is not 
responsible for nuclear deacetylation of SIRT2 targets, the possibility that this 
isoform would deacetylate other targets cannot be ruled out. Moreover, it is possible 
that the newly discovered SIRT2 isoform 5 exhibits other functions than protein 
deacetylation, as described for other sirtuins. For example, SIRT4 acts as mono-ADP-
ribosyl transferase and was recently also characterized as a lipoamidase targeting 
subunit E2 (dehydrolipoyl dehydrogenase) of the pyruvate dehydrogenase complex, 
thereby inhibiting its activity [76]. Another example is the recent discovery of lysine 
glutarylation, a new five-carbon posttranslational modification found on CPS1 and 
inhibiting this enzyme. SIRT5 was identified as the enzyme responsible for removal 
of lysine glutarylation on CPS1.  
Alternatively, SIRT2 isoform 5 may have functions independent of any catalytic 
activities. Such roles have previously been described for SIRT1. Proteolytic cleavage 
of SIRT1 generates an inactive form of SIRT1, which can in turn be exported to the 
cytoplasm. In the cytoplasm, the fragment of SIRT1 associates with the outer 
mitochondrial membrane and blocks the assembly of cytochrome c with the 
apoptosome complex, thus protecting cells from apoptosis [148]. SIRT1 was also 
found to promote neuroprotection independently of its catalytic activity. Indeed 
overexpression of SIRT1 protects neurons from cell death, an effect still visible when 
catalytically dead mutant SIRT1 is overexpressed, or in presence of SIRT1 inhibitors 
[149].  
Whether the hereby-presented new isoform of SIRT2 deacetylates other targets, or 
has alternative functions will have to be clarified by future investigations.  
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4.1.2 NAD biosynthetic enzyme NMNAT3 is localized to the 
mitochondria 
Another aspect of this study was to examine the question of NAD biosynthesis within 
mitochondria. While NAD+ is generally considered to freely distribute between the 
nucleus and cytoplasm, the presence of an impermeable inner membrane in 
mitochondria prevents that NAD+ freely distributes from the cytosol to this organelle. 
Thus, two options may explain how the mitochondrial NAD+ pool is established and 
maintained: either a mitochondrial carrier imports NAD+, or it is synthesized within 
the mitochondria.  
To test the possibility that mitochondrial NAD+ is imported by a transporter, the 
ability of three human candidate proteins to increase mitochondrial NAD+ was 
compared to that of previously described NAD+ carriers. Such mitochondrial NAD+ 
transporters have been identified in yeast (ScNDT1) [136] and in plants (AtNDT2) 
[137]. When overexpressed, none of these three human candidate proteins could 
increase mitochondrial NAD+ availability suggesting that they do not exhibit NAD+ 
transporter activities. These results are in accordance with a previous publication 
reporting that SLC25A32 has no influence on mitochondrial NAD+ [109]. 
Furthermore, during the preparation of Paper II, SLC25A33 or SLC25A36 were 
characterized as pyrimidine nucleotide transporters unable to transport NAD+ [150].  
The existence of a human mitochondrial NAD+ transporter cannot completely be 
ruled out. SLC25A32 could still be the human NAD+ carrier but may already be 
expressed at a very high level, in which case its overexpression may not result in any 
detectable changes in mitochondrial NAD+ availability. Furthermore, NAD+ could be 
imported into mitochondria by a transporter sharing little homology with the yeast 
and plant proteins, which could explain the difficulties encountered in the course of 
its identification. For example, the mitochondrial pyruvate carrier (MPC) was initially 
believed to be a member of the mitochondrial carrier family, which led to its 
misidentification [136,151,152].  
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Only later, it was found that the MPC is a heterocomplex formed by two members of 
a family of previously uncharacterized membrane proteins that are conserved from 
yeast to mammals [130,131].  
The alternative to direct import is intra-mitochondrial NAD+ biosynthesis. Previous 
work demonstrated that all NAD+ biosynthetic enzymes reside in the cytoplasm and 
nucleus, with the exception of the overexpressed recombinant NMNAT3, which is 
localized to the mitochondrial matrix [8]. The existence of human NMNAT3 protein 
in mitochondria was debated, mostly due to the challenges encountered in its specific 
immunodetection within these organelles. Whereas the mRNA has been detected in 
several studies [140,142,153], the mitochondrial localization of NMNAT3 had only 
been demonstrated for the overexpressed protein [8,141,142,153,154] and conclusive 
evidence of the presence of human endogenous NMNAT3 protein within the 
mitochondrial matrix was still lacking. The low expression levels of NMNAT3, 
combined with a possible low sensitivity of the antibodies used in those studies, may 
explain why the endogenous protein could not be detected. 
In this study, the presence in mitochondria of endogenous NMNAT3 protein was 
confirmed in HEK293 cells, and the protein could be readily immunodetected in 
extracts from different human cell lines (data not shown). Interestingly, comparison 
of NMNAT3 expression in 293mitoPARP and 293AtNDT2 showed that 
mitochondrial NAD+ availability appears to have no effect on NMNAT3 levels. 
Furthermore, preliminary experiments suggest that overexpression of NMNAT3 does 
not increase mitochondrial NAD+ availability (data not shown). Although these 
findings may be surprising, they are in line with previous studies showing that 
overexpression of NMNAT1 does not increase cellular NAD+ content [155-157].  
Taken together, these data strongly argue in favor of intra-mitochondrial biosynthesis. 
Interestingly, yeast and Arabidopsis thaliana express mitochondrial NAD+ 
transporters but lack an NMNAT3 homolog. Conversely, Helianthus tuberosus L 
(Jersualem artichoke) has a mitochondrial NMNAT [158], but a BLAST search failed 
to identify a putative gene coding for a NAD+ transporter of the Arabidopsis thaliana 
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type. This may suggest that mitochondrial NAD+ import and biosynthesis are two 
evolutionary separate mechanisms to establish the mitochondrial NAD+ pool, but may 
be mutually exclusive.  
Finally, given that all other NAD biosynthetic enzymes are located outside the 
mitochondria, if the mitochondrial NAD+ pool depends on autonomous biosynthesis, 
it still requires the substrate for NMNAT3, namely NMN. The absence of NamPRT 
from the mitochondria [8,133] indicates that NMN would have to be imported by a 
dedicated transporter. However, such a transporter remains to be identified. 
4.2 Distribution of NAD+ between cellular compartments 
affects the metabolic profile of human cells 
Previous work in our group demonstrated that a cell line stably expressing the 
catalytic domain of PARP1 targeted to the mitochondria exhibits a decrease of NAD+, 
resulting in cells far more dependent on glycolysis than the controls [134]. These 
findings raised the question as to what repercussions the opposite modulation, namely 
increased mitochondrial NAD+ availability, would have.  
Mitochondrial NAD+ availability was successfully increased by expression of 
mitochondrial NAD+ carriers ScNDT1 and AtNDT2, and a cell line stably expressing 
AtNDT2 (293AtNDT2) was established. Strikingly, the presence of the plant 
transporter strongly reduced cell proliferation and led to shift from oxidative 
phosphorylation to glycolysis as demonstrated both by lactate measurements, and 
determination of glycolytic rate and oxygen consumption. The finding that increasing 
mitochondrial NAD+ availability appeared to be harmful to human cells was 
unexpected, especially in the light of several reports highlighting the protective nature 
of mitochondrial NAD+. For example, mitochondrial NAD+ was shown to protect 
against genotoxic stess-induced cell death [109] whereas maintenance of 
mitochondrial NAD+ protects myocytes from death in the context if postischemic 
reperfusion of the heart [159].  
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Furthermore, inhibition of NAD biosynthesis with the NamPRT inhibitor FK866 
appears to have no effect on the mitochondrial NAD+ pool [133]. All these 
observations would thus suggest that increasing mitochondrial NAD+ availability 
would be beneficial for the cells.  
To understand this apparent contradiction, one should consider that the increase of 
mitochondrial NAD+ might be at the expense of the cytosolic pool. Should cytosolic 
NAD+ levels be lowered, maintenance of glycolysis would require a higher oxidation 
of NADH to NAD+, a reaction catalyzed by lactate dehydrogenase (LDH) and 
accompanied by the increased lactate formation measured in these cells. Moreover, 
oxidation of NADH would also require pyruvate as the substrate for LDH. Hence, it 
is reasonable to argue that under such conditions, pyruvate would serve as substrate 
to LDH rather than mitochondrial respiration, which would translate into the low 
oxygen consumption rate of these cells. In line with this hypothesis, recent findings 
linked PARP1 activation in response to DNA damage to inhibition of glycolysis and 
mitochondrial respiratory failure, a phenotype reversed by the addition of pyruvate. 
These results indicated that impaired mitochondrial respiration was the consequence 
of lower pyruvate availability in response to glycolysis inhibition [160,161]. 
Whereas the results presented here are in accordance with such a mechanism, one 
aspect that has to be considered is the nature of the transporter. AtNDT2 was 
characterized as a member of the mitochondrial carrier family working in a counter-
exchange mode. This type of exchange implies that when NAD+ accumulates in the 
mitochondria, the counter substrate should accumulate in the cytosol. In plants, AMP 
and ADP are the most efficient counter substrates for the antiporter AtNDT2 [137]. 
Redistribution of these nucleotides could also affect the metabolic profile of 
293AtNDT2 cells. For example, higher concentrations of AMP in the cytosol could 
activate the AMPK pathway resulting in the activation of glycolysis [162]. Whereas 
AMPK activation may contribute to the increased glycolytic rate, this hypothesis fails 
to explain the failure in mitochondrial respiration and the increased lactate 
production. Furthermore, activation of glucose catabolism by AMPK is a feature of 
insulin-dependent tissues such as liver, adipose tissue and muscle.  
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Thus, it is unlikely to contribute significantly to the effects observed in HEK293 
cells, a cell line likely originating from transformation of an embryonic adrenal gland 
cell, and sharing many features with neuronal cells [163,164].  
As ADP is the substrate for ATP synthase, a putative ADP withdrawal from the 
mitochondria may also lower basal mitochondrial respiration and favor glycolysis. 
However, mitochondrial ADP shortage would not affect the oxygen consumption rate 
in the presence of the uncoupler, an effect observed in the 293AtNDT2 cells.  
A similar shift from respiration towards glycolysis also occurred upon increased 
consumption of mitochondrial NAD+ (293mitoPARP). Although both mitochondrial 
NAD+ modulations result in the same phenotype, in 293mitoPARP, the decrease in 
mitochondrial NAD+ availability is likely to be responsible for reduced mitochondrial 
respiration, which in turn would be compensated for by increasing the glycolytic rate. 
Though it was surprising that seemingly opposite mitochondrial NAD+ modulations 
resulted in similar metabolic profiles, comparable observations have been reported in 
yeast: overexpression as well as deletion of mitochondrial NAD+ carriers lowers ATP 
production, and upon complete respiratory growth conditions both mutants exhibited 
a low biomass yield indicating impaired respiratory functions [165]. 
Although similar with regards to their metabolic profiles, 293mitoPARP cells and 
293AtNDT2 cells exhibited different behaviors in several aspects. One of the most 
striking phenotype of the 293AtNDT2 cells is their substantially impaired growth 
rate. Possibly, the continuous drainage of NAD+ from the cytosol and the necessity to 
replenish that pool may affect the ability of cells to produce acetyl-CoA from 
pyruvate, and this to an extent severely affecting cell proliferation. Moreover, a 
decrease in cytosolic NAD+ would in turn reduce the ability of SIRT1 to deacetylate 
and activate AceCS1 thus also lowering acetyl-CoA production in the cytosol [47]. 
Reducing acetyl-CoA availability would subsequently affect acetylation of histones 
and transcription factors involved in cell proliferation but also negatively affect lipid 
biosynthesis, hence lowering the availability of “building blocks” necessary for cell 
proliferation.  
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On the other hand, mitochondrial NAD+ consumption in 293mitoPARP might be 
sufficiently compensated for to maintain the proliferation, and would not affect the 
cytosolic NAD+ content.  
Importantly, mitochondrial NAD+ levels appear to dictate the extent of cell survival 
upon treatment with the NamPRT inhibitor FK866. As previously reported, NamPRT 
inhibition leads to severe NAD+ depletion and subsequent cell death [8,166], an effect 
enhanced when mitochondrial NAD+ is lowered. On the contrary, accumulation of 
NAD+ within the mitochondria in 293AtNDT2 cells conferred a protective effect 
towards NAD+-depletion-mediated cell death. The slow proliferation of these cells 
could translate into lower NAD+ consumption enabling longer survival in presence of 
FK866. In line with this hypothesis, inhibition of PARP1 also increases tolerance to 
inhibition of NAD+ biosynthesis [8,133,167]. 
Reshuffling of NAD+ from the cytosol to the mitochondria thus resulted in dramatic 
changes in the metabolic profile of human cells, characterized by severe deleterious 
effects on mitochondrial respiration and cell proliferation. As such, the data obtained 
here demonstrate that appropriate distribution of cellular NAD+ is important to 
maintain healthy metabolism in human cells. 
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5. Concluding remarks and future perspectives 
The results presented in this dissertation have significantly extended our knowledge 
of NAD+- related processes in the context of a compartmentalized cell, but also raised 
a significant amount of exciting questions. 
This work led to the identification and characterization of a new human splice variant 
of SIRT2 but further investigations will be required to understand the physiological 
relevance of this isoform. In the frame of this study, deacetylation activity of SIRT2 
isoform 5 could not be detected. However, the scope of targets and activities tested 
could be enlarged in order to further verify the activity of the isoform 5. Although the 
expression was rather weak, the presence of the mRNA coding for isoform 5 was 
confirmed in several cell lines. It will be interesting to screen more cell lines in order 
to determine if some cell lines, or tissues, express isoform 5 at higher levels, and if 
the endogenous protein can be detected. If such samples can be identified, specific 
knockdown by interfering RNA may bring important information with regards to the 
role played by this isoform. Given that the new nuclear SIRT2 isoform exhibited no 
apparent activity, the mechanisms underlying the deacetylation of nuclear targets by 
the cytosolic SIRT2 could not be solved. The contribution of the predicted nuclear 
localization signal will have to be further investigated. Indeed, mutations and/or 
deletion of the NLS in SIRT2 isoform 5 should determine whether the prediction is 
accurate. Upon confirmation of the NLS, it will be interesting to determine whether 
the absence of the NLS in SIRT2 isoforms 1 or 2 affects deacetylation of nuclear 
targets.  
Regarding mitochondrial NAD metabolism, the work presented here provides 
conclusive evidence of the existence of a mitochondrial NMNAT protein. This 
finding sheds new light on the topic of how the mitochondrial NAD+ pool is 
established and suggests several interesting experiments.  
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According to the hypothesis that NMNAT3 is responsible for NAD biosynthesis 
within the mitochondrial matrix, knockout of this protein, for example, by means of 
the CRISPR-cas9 method, should affect mitochondrial NAD+ availability to a great 
extent. In turn, the putative NAD+-depletion could affect, among others, the 
metabolic profile, cell survival, or mitochondrial acetylation. For example, NMNAT3 
knockout cells and 293mitoPARP cells may exhibit similar metabolic phenotypes. If 
such observations can be made, it will be interesting to test whether the presence of 
the plant transporter AtNDT2 results in desensitization of cells towards the knockout 
of NMNAT3. Additional work will also be required to understand how the substrate 
of NMNAT3, namely NMN, enters the mitochondria. It is generally accepted that 
NamPRT, the enzyme generating NMN, resides in the cytoplasm, suggesting that 
NMN is imported in mitochondria by a transporter. To date, this carrier remains to be 
identified.  
The results obtained in this work thus support the conclusion that NAD is synthesized 
within mitochondria rather than imported by a transporter. While the possibility that a 
human NAD+ transporter exists cannot be ruled out based on these data, the necessity 
for human mitochondrial NAD+ import might be alleviated by the presence of 
NMNAT3 inside these organelles. 
Finally, this study reveals that modulation of mitochondrial NAD+ has severe 
consequences on important cellular processes, and opens up new perspectives. First, 
the hypothesis that pyruvate is diverted away from mitochondrial respiration towards 
lactate dehydrogenase will have to be tested. Failure of mitochondrial respiration 
resulting from PARP1 activation is rescued by addition of pyruvate [160,161]. 
Seahorse experiments could be performed to verify whether the oxygen consumption 
rate of the 293AtNDT2 cells can be rescued by addition of pyruvate. Moreover, 
supplementation with pyruvate may also have beneficial effects on the cell 
proliferation. Second, modulating mitochondrial NAD+ availability may result in 
changes in mitochondrial sirtuin activity, and for example, acetylation levels of 
mitochondrial proteins may be altered.  
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Preliminary results indicate that global mitochondrial acetylation does not, however, 
change upon consumption or increase in mitochondrial availability. Future 
experimental approaches will have to determine whether acetylation or ADP-
ribosylation of specific targets is affected by changes in mitochondrial NAD+ 
concentrations.  
Third, a major challenge in the future will be to accurately determine the 
concentration of NAD+, for example in the mitochondria and the cytosol. Such 
measurements are critical and rendered difficult by the need for a method sensitive 
enough for cell samples. In this context, high performance liquid chromatography 
coupled to mass spectrometry (LC-MS) is becoming the leading analytical method in 
the measurement of nucleotides in cell extracts [110]. This method will surely enable 
the quantification not only of NAD but also of other nucleotides such as ADP-ribose, 
ATP, and ADP in organelles and compartments.  
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Abstract
Sirtuin-2 (SIRT2), the cytoplasmic member of the sirtuin family, has been implicated in the deacetylation of
nuclear proteins. Although the enzyme has been reported to be located to the nucleus during G2/M phase, its
spectrum of targets suggests functions in the nucleus throughout the cell cycle. While a nucleocytoplasmic
shuttling mechanism has been proposed for SIRT2, recent studies have indicated the presence of a
constitutively nuclear isoform. Here we report the identification of a novel splice variant (isoform 5) of SIRT2
that lacks a nuclear export signal and encodes a predominantly nuclear isoform. This novel isoform 5 fails to
show deacetylase activity using several assays, both in vitro and in vivo, and we are led to conclude that this
isoform is catalytically inactive. Nevertheless, it retains the ability to interact with p300, a known interaction
partner. Moreover, changes in intrinsic tryptophan fluorescence upon denaturation indicate that the protein is
properly folded. These data, together with computational analyses, confirm the structural integrity of the
catalytic domain. Our results suggest an activity-independent nuclear function of the novel isoform.
© 2013 Elsevier Ltd. All rights reserved.
Introduction
Members of the sirtuin family of NAD+-dependent
deacetylases are modulators of various cellular
processes including metabolic homeostasis, cell
cycle control, development and chromatin organiza-
tion [1–6]. Consequently, the regulation of sirtuin
activity, for example, by alteration of expression levels,
posttranslational modifications or subcellular compart-
mentation [7–12], is a key issue for normal cellular
function. A total of seven human sirtuin homologues
(SIRT1–SIRT7) with distinct cellular locations have
been identified.
SIRT1, SIRT6 and SIRT7 are primarily localized
to the nucleus, while SIRT3, SIRT4 and SIRT5 are
mitochondrial proteins, and SIRT2 has a predominant
cytosolic localization [13–15]. Moreover, several
reports suggest that the presence of some sirtuins is
not confined to a single subcellular compartment.
Localization of SIRT1 was found to be tissue specific
in mice with either nuclear, cytoplasmic or nucleocy-
toplasmic distribution [16,17]. SIRT3 contains a
mitochondrial targeting signal and, hence, localizes
predominantly to the mitochondria but also displays a
partial nuclear localization [18,19]. Similarly, SIRT5
does not only localize to the mitochondria but can be
retained in the cytoplasm [9], while a cell cycle-
dependent shuttling from the cytosol to the nucleus
has been reported for SIRT2 [20].
The molecular mechanisms and functional conse-
quences underlying the different cellular distributions
of sirtuins are so far poorly understood. It has been
shown that the activation of the phosphatidylinositol
3-kinase pathway in myoblast cells leads to alteration
in the subcellular localization of SIRT1 [16,17]. This is
achieved by control of the two nuclear localization
signals (NLSs) and two nuclear export signals (NESs)
in the primary structure of SIRT1 via posttranslational
modifications [17]. For SIRT5, subcellular localization
is regulated by alternative splicing, affecting the amino
acid composition at the C-terminal end of the protein.
One of the SIRT5 splice variants contains a GPCG
motif that is required for retaining the protein in the
cytoplasm, whereas the C-terminus of the other may
anchor the protein in the outer mitochondrial mem-
brane [9].
0022-2836/$ - see front matter © 2013 Elsevier Ltd. All rights reserved. J. Mol. Biol. (2014) 426, 1677–1691
Article
For SIRT2, four different human splice variants are
deposited in the GenBank sequence database.
However, only transcript variants 1 and 2 have
confirmed protein products of physiological relevance.
A leucine-rich NES within the N-terminal region of
these two isoforms was identified. Since deletion of
the NES led to nucleocytoplasmic distribution, it was
suggested to mediate their cytosolic localization [21].
Cytosolic functions of SIRT2 include the regulation of
microtubule acetylation, control of myelination in the
central and peripheral nervous system and gluconeo-
genesis [15,22–24]. There is growing evidence for
additional functions of SIRT2 in the nucleus. During
the G2/M transition, nuclear SIRT2 is responsible for
global deacetylation of H4K16, facilitating H4K20
methylation and subsequent chromatin compaction
[3,20,25]. This process links SIRT2 to maintenance of
genomic integrity and may thus explain, at least in
part, why SIRT2-deficientmice show elevated rates of
tumorigenesis. In response to DNA damage, SIRT2
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was also found to deacetylate H3K56 in vivo [26].
Finally, SIRT2 negatively regulates the acetyltrans-
ferase activity of the transcriptional co-activator p300
via deacetylation of an automodification loop within its
catalytic domain [26–28].
The characterization of SIRT2 isoforms as cyto-
solic proteins is in apparent contradiction with the
reported nuclear functions. Earlier studies, which
indicated the nuclear accumulation of SIRT2 after
CRM1 inhibition of protein export from the nucleus,
suggested the presence of a nucleocytoplasmic
shuttling mechanism for SIRT2 [21,29]. However, a
functional NLS has not been detected in the SIRT2
primary structure [21]. Additionally, the NES is
present in both known isoforms, which indicates a
passive form of nuclear accumulation. This raises
the question as to how the nuclear presence of
SIRT2 is brought about. In mice, another Sirt2 splice
variant was demonstrated [24,30]. Interestingly, the
corresponding protein would lack the amino acids
that constitute the NES in the human isoforms.
On the basis of these findings, we asked whether
additional isoforms for human SIRT2 that result from
alternative splicing of the primary transcript exist. We
here demonstrate the identification of an alternative-
ly spliced transcript, which results from skipping of
exons 2–4 and encodes a novel SIRT2 isoform that
we have designated as isoform 5. The new isoform is
predominantly localized in the nucleus and does
not exhibit any detectable deacetylase activity as
demonstrated in several assays. However, the
protein appears to be properly folded and retains
the ability to bind p300. Unless isoform 5 requires
other, as yet unidentified, cofactors for activity, our
data suggest a non-catalytic, nuclear function for
SIRT2 isoform 5.
Results
Alternative splicing of the primary transcript
results in a hitherto unrecognized human SIRT2
splice variant
First we verified the presence of the reportedmurine
splice variant that lacks the NES encoding sequence
[30] in complementaryDNA (cDNA) preparations from
murine brain tissue and NIH-3T3 cells by PCR using
primers specific for sequences in exon 1 and exon 10
of the Sirt2 gene. We amplified three DNA fragments
of approximately 750, 700 and 550 bp in length
(Fig. 1a, top panel). The isolated ~550 bp fragment
was reamplified (Fig. 1a, middle panel). DNA se-
quence analysis confirmed these DNA fragments to
originate from the reported splice events containing all
exons (isoform 1), leading to skipping of exon 2
(isoform 2) or exons 2–4 (isoform 3) (Fig. 1a, bottom
panel). To investigate whether the human primary
SIRT2 transcript is subject to a similar splicing event,
we performedPCRswith primers spanning exons 1–8
using cDNAs derived from seven human cell lines as
templates. DNA fragments of ~800 bp and ~750 bp
were amplified, which correspond to the knownSIRT2
isoforms 1 and 2 (Fig. 1b, top panel). An additional
fragment of ~550 bp in length was consistently
co-amplified in all reactions (Fig. 1b, top panel) and
was reamplified after gel purification (Fig. 1b, middle
panel). DNA sequencing analysis showed that this
Fig. 1. Identification of a novel human SIRT2 splice variant. PCR analyses of cDNAs derived from mouse (a) and
human (b) sources. The exon composition and length of the amplified DNA fragments is shown below the agarose gels,
and triangles indicate the location of primer sequences. The size of selected marker bands (bp) is indicated. Control
reactions (cntr) were run in the absence of cDNA. (a) PCR analysis of cDNA preparations from murine brain tissue and
NIH-3T3 cells. Samples were run in 2% ethidium bromide-stained agarose gels. The major product of the reactions from
both templates was a 748-bp fragment derived from the transcript encoding isoform 1 (iso 1), and a second product of
701 bp resulted from the isoform 2-specific mRNA (iso 2). A third DNA fragment running at ~550 bp could be specifically
reamplified after gel purification (middle panel) and was identified as specific 538-bp sequence originating from a murine
Sirt2-transcript variant (iso 3) lacking exons 2–4. (b) PCR analysis of cDNA preparations from seven human cell lines.
Amplified fragments were separated in a 2% agarose gel. The two major products of the amplification corresponded to
human SIRT2 isoforms 1 and 2 (758 bp and 711 bp, respectively). A third DNA fragment running at ~550 bp could be
specifically reamplified after gel purification (middle panel) and was identified as specific 548-bp sequence originating from
a novel human SIRT2-transcript variant (iso 5) lacking exons 2–4. (c) Overview of the isoform-specific SIRT2 splicing
events occurring on the human primary transcript. Exon 1 is linked via a common splice donor site with the common splice
acceptor sites in exon 3 (to process transcript variant 2) and to exon 5 (for maturation of transcript variant 5). Exons 1 and 3
constitute the 5′-UTR of transcript variant 2. The ORF starts at an AUG triplet that is formed directly at the transition from
exon 3 to exon 4. Alternative splicing of exons 1 and 5 leads to the substitution of the codons for amino acids 6–76 of the
full-length ORF of isoform 1 by an arginine codon in isoform 5. (d) The ORFs of the different SIRT2 isoforms were
expressed as C-terminal V5-His-tagged proteins in the context of the endogenous 5′-UTRs of the corresponding mRNAs.
The molecular masses of the different SIRT2 isoforms (including V5-His tag) were predicted to be 46.7 kDa (isoform 1),
43 kDa (isoform 2) and 39.1 kDa (isoform 5). The V5-epitope was used for immunodetection. Expression of isoform 1 from
a transcript harboring its physiological 5′-UTR (iso 1) leads to detection of an additional weakly expressed protein that
corresponds in size to SIRT2 isoform 2 (right panel). In the context of the endogenous 5′-UTR, mutation of the start codon
of the isoform 1- specific transcript (iso 1 r.343u N a) leads to translation of isoform 2 as the sole protein. Lysates from cells
transfected with the vector backbone were used as control (cntr).
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third PCRproduct originated from a splicing event that
links exon 1 to exon 5 (Fig. 1b, bottom panel).† The
presence of this splicing event was further supported
by analyses of expressed sequence tags (GenBank)
from human and Sumatran orangutan tissues.
We then asked whether there are further alternative
splicing events downstream of exon 5 in the identified
transcript. Nested PCRs were performed in order to
amplify the full-length messenger RNA (mRNA) of the
novel transcript variant. cDNA preparations from 293
and SH-SY5Y cells were subjected to primary PCRs
using primers spanning exons 1–16. Three secondary
PCRswere carried out using (i) a primer pair spanning
the 5′-untranslated region (UTR) to the exon 1/5
junction, (ii) a primer pair spanning the exon 1/5
junction to exon 16 and (iii) a primer pair spanning
exons 1–16 (Fig. S1, bottom panel). All reactions led
to amplification of specific products. DNA sequence
analysis revealed no further alternative splicing
events downstream of exon 5 of the novel human
SIRT2 splice variant. Thus, the novel human SIRT2
transcript is composed of exon 1 and exons 5–16
(Fig. S1). The open reading frame (ORF) starts from
the same AUG triplet in exon 1 that is used to initiate
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translation of SIRT2 isoform 1 and terminates in exon
16 at the common stop codon for all (known) SIRT2
isoforms (Fig. 1c). As transcripts variants 3 and 4 are
already deposited in GenBank database,‡ the novel
human SIRT2 isoform encoded by the alternative
splicing events reported here is designated isoform 5.
Since we could not identify sequences corresponding
to transcript variants 3 and 4, all subsequent
experimentswere carried out using the three identified
transcript variants 1, 2 and 5.
Next, we analyzed whether the composition of the
5′-UTRs of the three humanSIRT2mRNAsmay affect
the translation into proteins. To this end, we expressed
C-terminally V5-His-tagged SIRT2 isoforms 1, 2 and 5
in the context of their endogenous 5′-UTRs in 293 cells.
Immunoblot analyses showed expression of C-termi-
nally V5-tagged proteins of expected size (Fig. 1d).We
also observed a weak band corresponding in size to
isoform2 in cells transfectedwith the plasmid encoding
isoform 1 (Fig. 1d, right panel). When the start codon of
isoform 1 was mutated (r.343u N a), we observe a
band pattern identical with the one seen for wild-type
(wt) isoform 2 (Fig. 1d, r.343u N a). This observation
suggests that the second AUG triplet within the ORF
of isoform 1 may be used as alternative start codon
leading to leaky co-translation of isoform 2. Thus,
co-translation of SIRT2 isoform 2 from the transcript
encoding isoform 1 may be of relevance in vivo.
Predominant nuclear localization of human
SIRT2 isoform 5
Compared to isoform 1, alternative splicing events of
the SIRT2 primary transcript result in N-terminal
truncation (residues 1–37) of isoform 2 and, for isoform
5, in the substitution of residues 6–76 by an arginine
residue (Fig. 2a and Fig. S2). As a consequence, the
catalytic domain (defined here as residues 64–336 by
multiple sequence alignment and structure analysis) is
slightly truncated. However, a conservation analysis
using the phylogenetic dataset described by Frye
[31] indicated that neither highly conserved residues
nor amino acids involved in co-substrate binding
would be affected by the changes in the primary
structure (Fig. 2a). Importantly, N-terminal amino
acids that are absent from isoform 5 represent the
reported NES found in the other isoforms. Therefore,
isoform 5 may display a different cellular distribution
thanSIRT2 isoforms 1 and 2. To address this question,
we investigated subcellular localization of C-terminally
V5-His-tagged SIRT2 isoforms in HeLa S3 and 293
cells. To avoid expression of isoform 2 from the
construct encoding isoform 1, we included a mutant
form of isoform 1 (M38A) to eliminate the alternative
translational start site for isoform 2 (Fig. 2b). As
expected, V5 immunocytochemistry showed predom-
inant cytoplasmic localizations of isoforms 1 (wt and
M38A) and 2. In contrast, isoform 5 localized primarily
to the nucleus (Fig. 2c). This finding was substantiated
by immunoblot analyses of subcellular fractions from
293 cells (Fig. 2d).
SIRT2 isoform 5 is catalytically inactive in vitro
and in vivo
Next, we asked whether the lack of amino acids
encoded by exons 2–4 in isoform 5 might change the
catalytic properties of this protein. The deacetylase
activities of purified SIRT2 isoforms were measured
using the CycLex SIRT2 fluorometric activity kit.
Isoform 5 showed no detectable activity, whereas
isoforms 1 (wt and M38A) and 2 showed a robust
deacetylase activity toward the fluoro-peptide
(Fig. 3a). Lack of activity when measuring mutant
proteins (H N Y) in which the essential proton acceptor
histidine 187 (isoform 1) was replaced by tyrosine
confirmed the specificity of the reactions.
Given that isoform 5 contains all residues predict-
ed to be required for catalysis, the lack of deacetyla-
tion activity of this isoform was a rather unexpected
Fig. 2. SIRT2 isoform 5 predominantly localizes to the nucleus. (a) Alternative splicing of the human SIRT2 pre-mRNA
leads to three distinct proteins. The ORF of isoform 2 starts at a methionine codon formed at the exon 3/4 transition,
thereby shortening isoform 2 by the first 37 amino acids relative to isoform 1. In SIRT2 isoform 5, amino acids 6–76 of
isoform 1 are exchanged by an arginine leading to the removal of the NES (indicated by the red box). Secondary structure
is given with gray rectangles representing α-helices and orange arrows representing β-sheets. The degree of conservation
was calculated from multiple sequence alignment (gaps matching non-SIRT2 residue were removed) with a score range
from 1 to 10 reflecting conservation of biophysical properties of residues and a maximum score of 11 for absolute
conservation. The catalytic domain is indicated in green; flanking N- and C-terminal regions, in brown; residues involved in
co-substrate coordination and catalysis, in gray; zinc-coordinating residues, in white. All annotation correspond to the
reported structures (PDB IDs: 3ZGO and 3ZGV) [42]. (b) V5-immunoblot analysis of lysates from 293 cells transiently
expressing SIRT2 isoforms. Overexpression of SIRT2 isoform 1 results in co-expression of isoform 2 by alternative
translational start from the second in frame AUG triplet. Mutation of methionine at position 38 to alanine (MA) in the ORF of
SirtT2 isoform 1 leads to sole detection of isoform 1. (c) The different SIRT2 isoforms were expressed in HeLa S3 cells and
cell lysates subjected to V5 immunocytochemistry. SIRT2 isoforms 1 (wt andMA) and 2 localize to the cytoplasm, whereas
isoform 5 is predominantly found in the nucleus. The bar represents 10 μm. (d) Cell fractionation of 293 cells transiently
overexpressing SIRT2 isoforms. Isoforms 1 (wt and MA) and 2 are detected in cytoplasmic fractions, whereas isoform 5 is
predominantly detected in the nuclear fraction. The purity of the cellular fractions was tested by probing the membranes
with α-tubulin and histone H3 antibodies.
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observation. Therefore, we extended our study to
include alternative activity assays. We analyzed
purified recombinant proteins for NAD+-dependent
deacetylase activity using nuclear targets such as
the hyperacetylated catalytic domain of p300 (HATc)
or chemically acetylated histones as substrates.
Immunoblot analysis with an acetyllysine antibody
showed a clear decrease in acetylation of both
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Fig. 3. SIRT2 isoform 5 is inactive for protein deacetylation in vitro. The deacetylation activity of recombinant SIRT2
isoforms was determined by four individual experimental approaches. Proteins carrying a mutation of the catalytic
important histidine residue (H N Y) were used as negative controls. The mutant SIRT2 isoform 1 (MA) was used to exclude
co-expression of isoform 2 from the recombinant DNA. (a) Deacetylase activity of purified SIRT2 isoforms toward an
acetylated peptide using CycLex SIRT2 Deacetylation Fluorometric Assay Kit (excitation, 485 nm; emission, 530 nm).
Data are background corrected and represent mean of relative fluorescence intensity changes ± SD of triplicate
measurements. (b) Purified SIRT2 isoforms were incubated with either recombinant HATc or chemically acetylated
histones in the presence and absence of 20 mM nicotinamide (Nam). The acetylation state of HATc and histone H3 and
H4 as determined by immunoblot analyses was used as readout. Control reactions (cntr) were performed in the absence of
any SIRT2 isoform. (c) Deacetylation activity in lysates from bacteria expressing the SIRT2 isoforms. The activity was
tested toward the same acetylated targets as in (b). Control reactions (cntr) were performed using lysates from bacteria
harboring the “empty” SIRT2 expression vector. (d) Deacetylation activity of SIRT2 isoforms in living cells. Bacteria were
transformed with prokaryotic HATc expression plasmid along with different vectors encoding SIRT2 isoforms. After
expression, the acetylation state of HATc in whole bacterial lysates was assessed by immunoblot analysis. Bacteria
harboring the “empty” HATc expression vector as well as cells co-transformed with the “empty” SIRT2 and the “empty”
HATc expression vector were used as controls.
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targets when using isoform 1 (wt and M38A) or 2 in
the reactions. In contrast, no deacetylation activity
was detected for isoform 5 (Fig. 3b).
To rule out inactivation of isoform 5 by the
purification procedure, we performed deacetylation
assays using lysates from bacteria expressing the
different SIRT2 isoforms. Similar to the experiments
with isolated proteins, bacterial lysates containing
isoforms 1 (wt and M38A) or 2 deacetylated HATc
and histones, whereas no activity was observed in
lysates from bacteria expressing recombinant iso-
form 5 (Fig. 3c).
HATc is hyperacetylatedwhen expressed in bacteria
[32]. Since NAD+ is also freely available in prokaryotic
cells, co-expression with SIRT2 may reduce the
degree of HATc acetylation [33]. As shown in Fig. 3d,
co-expression with SIRT2 isoforms 1 (wt and M38A)
and 2 substantially reduced HATc self-acetylation. In
contrast, co-expressed SIRT2 isoform 5 had no effect
on the acetylation state of HATc (Fig. 3d).
Together, these data suggest that SIRT2 isoform 5 is
inactive in vitro. To exclude the possibility of suboptimal
assay condition, for example, the lack of endogenous
cofactors, we overexpressed the different SIRT2
isoforms in HeLa S3 and monitored the acetylation
status of α-tubulin. In the presence of isoforms 1 (wt
and M38A) and 2, acetylation of α-tubulin at lysine 40
was substantially reduced. In contrast, expression of
SIRT2 isoform5,which is partially located in the cytosol
(Fig. 2c and d), did not affect the acetylation status of
α-tubulin (Fig. 4).
SIRT2 isoform 5 is properly folded and interacts
with HATc
To determine whether the alteration of the N-ter-
minal region of SIRT2 isoform 5 led to a structural
impairment of the catalytic domain and thus could
account for the apparent lack of deacetylase activity,
we first performed molecular modeling analyses
using homology and threading approaches. All
models generated are consistent with SIRT2 isoform
5 adopting a fold very similar to the solved structure
of SIRT2 isoform 1 (RMSD values between 0.1 and
0.9 Å over 249–274 residues) (Fig. 5a and Fig. S3).
Examination of the electrostatic surface potential
indicated no alterations of the peptide or NAD+ binding
surfaces. The most striking difference was a charge
inversion near the Rossmann fold due to the absence
of α-helix α1 (Fig. 5a, dotted circle). However, given
the relatively large distance to the catalytic region,
it appears rather unlikely that this charge inversion
would severely influence the enzymatic activity.
Theseanalyses suggest that the overall fold of isoform
5 is unlikely to be significantly different from those of
isoforms 1 and 2.
To substantiate these models, we compared the
sensitivity of the purified isoforms for denaturation by
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Fig. 4. SIRT2 isoform 5 is inactive for protein deacetylation in vivo. HeLa S3 cells expressing the different SIRT2
isoforms for 24 h were subsequently incubated with 400 nM TSA for 12 h. The cells were subjected to
co-immunocytochemistry to detect the V5-epitope and lysine 40-acetylated α-tubulin. Overexpressed SIRT2 isoforms 1
(wt and MA) and 2 show reduces immunoreactivity for acetylated α-tubulin, whereas isoform 5 causes no change in the
α-tubulin (K40) acetylation. The bar represents 10 μm.
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increasing concentrations of guanidinium hydrochlo-
ride (GdmCl) by monitoring changes in the intrinsic
fluorescence of tryptophan residues. There are three
tryptophan residues in SIRT2, all within or near the
catalytic domain (W208, W320 and W337, isoform 1;
Fig. S2). Complete denaturation (at a GdmCl concen-
tration of 6 M) was accompanied by a red shift,
indicating exposure to more polar environment, and
changes in intensity (Fig. 5b). The spectra for isoforms
1 and 2 indicate the reduction of a quenching influence
on at least one of the tryptophans and, hence, an
increase in fluorescence intensity during denaturation.
The denaturation profiles, obtained by measurements
at various GdmCl concentrations, are shown as the
ratios between the fluorescence intensity at 330 and
360 nm (Fig. 5c). Calculation of I330/I360 ratios effec-
tively filters off whole spectrum influences (such as
concentration differences) [34]. The denaturation
profiles indicate that unfolding occurs in at least
two steps. The lower initial I330/I360 ratio calculated
for isoforms 2 and 5, in comparison to isoform 1,
points toward an influence of the N-terminus in the first
denaturation step (Fig. 5c). The subsequent denatur-
ation profiles are comparable for all isoforms; thus, a
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similar ordered structure of all isoforms can be
assumed (Fig. 5c). The increase in fluorescence
intensity, and hence the release of the quenching
effect, coincides with the first denaturation event (data
not shown). The observed quenching may be due to
electron transfer or static quenching of the tryptophans
within the structure (W208 and W337) or a result of an
interaction between the C- or the N-terminal regions
with the surface tryptophan W330, or both.
These observations support the results of the
modeling approaches suggesting that the overall
structure of isoform 5 is not severely perturbed.
Therefore, we considered the possibility that isoform
5 might still possess the ability to interact with SIRT2
binding partners. A previous study demonstrated an
interaction of SIRT2 isoform 1 with the C-terminal part
of p300 including the HAT domain [28]. We investi-
gated whether the SIRT2 isoforms 2 and 5 retained
this property. Indeed, as shown in Fig. 5d, all SIRT2
isoforms specifically interacted with the core catalytic
domain of p300 in vitro. We occasionally observed
weak binding of SIRT2 isoforms to GST (glutathione
S-transferase). However, the specific interaction with
p300 was invariably far stronger for all isoforms.
Interestingly, an increase in the interaction was
observed in the presence of co-substrates (either
acetyl-CoA or NAD+). Since p300 is a substrate for
SIRT2 and vice versa [27,28], stronger binding in the
presence of co-substrate may indicate that the
interaction partially results from an enzyme–substrate
relationship. Noteworthy, the interaction of HATc and
isoform5 is also strengthened by the addition of NAD+
indicating that isoform 5 retained the structural features
to bind this nucleotide.
Discussion
In the present study, we have identified the novel
isoform 5 of human SIRT2. Our analyses show that it is
anevolutionarily conserved isoform that corresponds to
a previously reported splice variant, designated isoform
3, in mouse. As isoform 5 lacks the NES, it localizes
predominantly to the nucleus. Despite the presence of
an apparently intact SIRT2 catalytic domain, isoform 5
does not deacetylate known targets of SIRT2 isoforms
1 and 2. Nevertheless, it retains the overall protein fold
and the ability to interact with p300. These results
suggest a non-enzymatic function for this isoform,
which remains to be elucidated. Alternatively, the novel
isoform 5 might have a substrate specificity that is
different from that of the knownSIRT2 isoforms 1 and 2
or may require a hitherto unidentified cofactor.
Generation of SIRT2 isoforms by alternative
splicing and translation
The alternatively spliced transcript encoding iso-
form 5 has been detected in all human cell lines
analyzed. Additionally, the existence of a similar splice
variant in mice has been reported recently [24,30] and
was confirmed in this study. The discovery of this
splice variant in primates and rodents suggests that
isoform 5 is the result of an evolutionary selection and
not a coincidental “slippage” of the splicingmachinery.
In addition to alternative splicing, our results
point toward utilization of an internal start codon
as a second mechanism to regulate the presence of
isoforms 1 and 2. Earlier, it was shown that isoform
2 is expressed from plasmid carrying isoform 1 in the
presence of an artificial 5′-UTR [35]. Our experiments
utilizing the endogenous 5′-UTR of SIRT2 showed
expression of isoform 2 from the plasmid encoding
isoform 1. Moreover, mutation of the isoform 1 start
codon showed efficient expression of isoform 2. In the
context of the endogenous 5′-UTR, isoform 1 has a
moderately strong Kozak sequence (position −3:
cytosine; position +4: guanine), whereas the start
codon of isoform 2 is surrounded by a strong Kozak
sequence (positions −3 and +4: guanine) [36].
Consequently, the expression of isoform 2 in the
Fig. 5. SIRT2 isoform 5 is structurally intact and can interact with p300-HATc. (a) Comparison of the SIRT2 isoforms 1 and
5 structure predictions (upper panel). Models were generated using homology modeling (Swiss-Model: isoform 1, yellow;
M4T: isoform 5, blue gray). Model of isoform 1 differs from the solved structure (PDB ID: 3ZGO, RMSD: 0.069 Å) only in the
presence of a connection loop (red) between α-helices α0 and α1. Both α0 and α1 are absent in isoform 5. Note that α0 is only
resolved in chains A and B of the asymmetric unit of 3ZGO. The C- and N-termini (Ni1: isoform 1, Ni5: isoform 5) are indicated,
and the catalytic histidine (H187, isoform 1) is given in stick representation. Absence of α1 from the structure leads to an
alteration in the electrostatic surface potential at the lower site of the Rossmann fold, but not to an exposure of hydrophobic
patches (lower panel). In the surface potentialmap, blue represents positively charged, red represents negatively chargedand
white represents neutral areas. The black dotted circle indicates the position of α1, and the gray dotted line indicates the
beginning of the modeled loop. The structures were prepared with PyMOL. (b) Fluorescence emission spectra for SIRT2
isoforms in the absence (black) or presence (red) of 6 M GdmCl (excitation at 290 nm). Values were normalized to the
maximal emission of the folded protein. Spectra represent the average of four measurements and are buffer corrected. (c)
GdmCl denaturation of SIRT2 isoforms as monitored by intrinsic tryptophan fluorescence. The denaturation profile of the
SIRT2 isoforms in response to increased GdmCl concentration is shown as the ratios of fluorescence intensities at 330 and
360 nm (excitation at 290 nm) (left panel). Data represent means ± SD of quadruple measurements. The right panel shows
Coomassie-stained gel of SIRT2 isoforms used in the denaturation shift assay. (d) GST-pulldown assay using the GST-fused
catalytic domain of p300 (HATc) and SIRT2 isoforms. Prior to the pulldown, samples were incubated in the absence or
presence of co- substrates (acetyl-CoA or NAD+). The molar ratio of proteins (HATc/GST: SIRT2) was 1:5. SIRT2 binding to
HATc was monitored by acetyllysine and HATc immunoblot analyses. Recombinant GST was used as negative control.
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context of isoform 1 could be a result of leaky ribosome
scanning. That is, isoform 2may be generated from the
isoform 1 transcript in vivo and thus might contribute to
the differences in isoform expression observed in
murine tissues [30]. However, the favored expression
of isoform 1 from its endogenous 5′-UTR indicates that
isoform 2 originates predominantly from an isoform-
specific alternatively spliced mRNA. Since the isoform
5 was detectable when overexpressed in context of its
endogenous 5′-UTR, it is more than likely that it is also
readily translated from its endogenous mRNA.
The observed nuclear SIRT2 activity must be a
result of a catalytically active isoform. In light of our
study, two mechanisms to promote nuclear SIRT2
localization appear most plausible: Absence of the
NES (Ref. [21] and this study) or conditions of
CRM1-dependent export inhibition [21,29]. Our anal-
yses of the NES encoding region indicate that isoform
5 is the only splice variant that excludes the NES
from the primary structure. On the other hand, the
essentially exclusive cytoplasmic localization of
isoforms 1 and 2 indicates highly active CRM1-
dependent nuclear export. Consequently, it would
appear that the nuclear SIRT2 activity is likely a result
of low-level abundance of SIRT2 isoform(s) brought
about either by constant shuttling or by masking of the
NES, for example, in a nuclear complex.
Isoform 5 shows nuclear enrichment,
however, is catalytically inactive
The absence of the NES from isoform 5 immediately
suggested the possibility that itmight be localized to the
nucleus. Indeed, using both immunocytochemistry and
cell fractionation, we observed a predominant nuclear
localization of SIRT2 isoform 5. This pattern is distinct
from isoforms 1 and 2, which are solely cytoplasmic.
Considering the molecular size of SIRT2 isoform 5, an
active transport mechanism either by a non-canonical
NLS or “piggy-backing” in complex with other proteins
seems likely. Computational NLS prediction using
cNLS mapper [37] indicated the presence of a weak
bipartite NLS containing an extended linker region
(residues 342–375 in isoform 1). The weak score (2.8)
is in accordance with the observed partial cytoplasmic
localization of isoform 5 and, thus, may be a result of
low NLS activity.
Given that the known SIRT2 isoforms 1 and 2
localized to the cytoplasm (Refs. [13–15] and this
study), it appeared likely that the new nuclear isoform
could account for the SIRT2-dependent deacetylation
of nuclear proteins. Surprisingly, in contrast to isoforms
1 and 2, isoform 5 displayed no catalytic activity in our
experiments. The absence of detectable activity in
multiple approaches and experimental systems pro-
vides compelling evidence that the novel SIRT2
isoform has no deacetylase activity, at least toward
known SIRT2 targets (Refs. [27,38–40] and confirmed
here): When using isolated, recombinant SIRT2
isoform 5, it neither deacetylated the fluorogenic
peptide nor histones or HATc of p300. Moreover,
when expressed and directly analyzed in bacterial or
human cells, isoform 5 exhibited no deacetylase
activity, whereas isoforms 1 and 2 were active. Thus,
even though isoform 5 provided an excellent candidate
to account for nuclear SIRT2 activity, our results seem
to rule out such a function.
The fold of the catalytic domain of SIRT2 isoform
5 is not substantially impaired
An obvious explanation for the catalytic inactivity
of isoform 5 would have been the lack of the most
N-terminal part of the catalytic domain (including
α-helix α1). The absence of these 12 residues could
either cause structural impairment or involve cata-
lytic residues. Several lines of evidence suggest,
however, that this is not the case. For example,
isolation of recombinant isoform 5 after expression in
bacteria resulted in a readily soluble protein. Moreover,
analyses of the tryptophan fluorescence during
GdmCl-dependent denaturation further indicated that
isolated isoform 5 is properly folded. These experi-
ments were also in line with our structural model that
predicts the catalytic core of isoform 5 to resemble that
of isoforms 1 and 2. All residues known to be essential
for catalysis [41,42] are still present in isoform 5.
However, comparison with the structure of SIRT2
isoform 1 revealed that α-helix α1 is missing in isoform
5. Sinceα1 is part of theNAD+-bindingRossmann fold,
the structural integrity of isoform 5 could be affected.
However, the modeling using homology and threading
approaches indicates that the general structure could
still be maintained. This is supported by a crystallo-
graphic study of cobB, a bacterial sirtuin homologue
[43]. The cobB protein used in that study lacked
the equivalent α-helix in the Rossmann fold but was
catalytically active.
Examination of the denaturation curves suggests
that, at least, one of the tryptophans of isoform 1 is in
labile environment created by the presence of the
N-terminal region. Shortening of the N-terminus
(isoform 2) or its removal (isoform 5) leads to an
increased solvent exposure as indicated by the drop in
the I330/I360 ratio. Considering the positioning of the
tryptophans within the structure, it is likely that either
the N-terminus folds back onto the catalytic domain
shielding the surface tryptophan W320 (isoform 1) or
helix α15 separates from the core structure exposing
W337 (isoform 1). Both changes could have an
indirect influence on the substrate binding capability
of SIRT2 without altering the major fold. An additional
indication that the observed inactivity of isoform 5 is
likely to be a result of more subtle conformational
differences is its preserved ability to interact with the
catalytic domain of p300. The latter feature is shared
by isoforms 1 and 2. The strengthened interaction
observed for all three isoforms in the presence of
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either co-substrate (acetyl-CoA for p300 or NAD+ for
SIRT2) indicates that the interaction is partially due to
the enzyme–substrate relationship of the two proteins.
Moreover, the noticeably enhanced binding of SIRT2
isoform 5 to HATc in the presence of NAD+ strongly
suggests that isoform 5 has retained the capacity to
bind NAD+.
Together, these results indicate that subtle structural
differences are responsible for the apparent catalytic
inactivity of isoform 5. Still, there exists a possibility that
isoform 5 has altered substrate specificity or that
nuclear interaction partners restore its catalytic activity.
It is interesting to note in this regard that deacetylation
of tubulin appears to be mediated by a complex
containing both SIRT2 and the NAD+-independent
deacetylase HDAC6 [15,44,45]. It has been proposed
that HDAC6 is a constitutive active deacetylase,
whereas the SIRT2 tubulin–deacetylase activity, but
not its ability to interact with HDAC6, is regulated by
phosphorylation of S368 (isoform 1) [15,44,46]. This
would suggest that SIRT2 has an additional deacety-
lase activity-independent function within the complex.
By analogy, itmight bepossible that isoform5mediates
nuclear protein interactions, for example, with p300,
perhaps, even in a NAD+-dependent manner.
It is also interesting to note that a non-catalytic
function has been described for SIRT1. Proteasomal
cleavage of SIRT1 in the C-terminal region renders the
enzyme catalytically inactive without affecting the
structure of the conserved core domain. The resulting
inactive fragment translocates from the nucleus to
the mitochondria where it protects from apoptosis
by interfering with apoptosome assembly [47]. The
regulation of cellular processes by non-catalytic
splice variants is, however, not limited to sirtuins
but is a more common phenomenon observed for
a variety of enzymes including DNAmethyltransferase
DNMT3B, protein phosphatase 2α and GTP cyclohy-
drolase I [48–50]. Future studies will have to explore
the physiological roles of the novel SIRT2 isoform
and thereby establish whether these include regu-
lated catalytic activity or exclusively non-catalytic
functions.
Materials and Methods
Antibodies
Rabbit polyclonal acetylated lysine antibody and rabbit
monoclonal acetyl-α-tubulin (K40) antibody (D20G3) were
from Cell Signaling Technology. Rabbit polyclonal GST (Z-5)
antibody was from Santa Cruz Biotechnology, mouse
monoclonal α-tubulin antibody (B-5-1-2) was from Sigma-
Aldrich, rabbit polyclonal histone H3 antibody was from
Millipore and mouse monoclonal V5-epitope antibody (1H6)
was from MBL International. Fluorescence-conjugated
secondary antibodies (Alexa Fluor 488-conjugated goat
anti-mouse and anti-rabbit; Alexa Fluor 594-conjugated
goat anti-mouse) were from Invitrogen/Life Technologies.
Horseradish-peroxidase-conjugated secondary goat anti--
mouse and anti-rabbit antibodies were from Pierce.
Cell culture
143B, 293 (HEK-293), A-431 and NIH-3T3 cells were
cultivated in high glucose DMEM (Dulbecco's modified
Eagle's medium) supplemented with 10% FCS, 2 mM
L-glutamine, penicillin (10,000 units/ml) and streptomycin
(10 mg/ml). HeLa S3 cells were cultivated in HAM's F12
medium, HepG2 and U-87 cells were grown in EMEM and
MCF-7 cells were grown in IMDM. All media were
supplemented with 10% FCS and penicillin/streptomycin.
SH-SY5Y cells were grown in a 1:1 mixture of high glucose
DMEM and HAM's F12 medium supplemented with 15%
FCS, penicillin/streptomycin, 2 mM L-glutamine and 1%
non-essential amino acids solution. Cells were incubated
at 37 °C in humidified atmosphere with 5% CO2.
Transfection of cultured human cells
Cells were seeded 24 h prior transfection. HeLa S3 cells
were transfected using Effectene (Qiagen), and 293 cells
were transfected using CalPhos Mammalian transfection
reagent (Clontech) according to the manufacturer's
recommendations.
Preparation of cell lysates and immunoblot analysis
Cells were washed twice with PBS and lysed with
20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM ethylene-
diaminetetraacetic acid and 1% (w/v) SDS. Genomic DNA
was disrupted by sonication and insoluble material
removed by centrifugation. Protein concentration of
supernatant was determined by BCA protein assay
(Pierce). After SDS-PAGE and protein transfer onto
nitrocellulose membranes, immunoblot analyses were
carried out using primary and secondary antibodies as
indicated. Proteins were detected by enhanced chemilu-
minescence (Pierce) and images were taken with a
ChemiDoc XRS+ system (Bio-Rad).
Reverse-transcription PCR analysis
Reverse transcription of total RNA, isolated from murine
brain tissue, 293, 143B, A-431, HeLa S3, HepG2, MCF-7,
NIH-3T3, SH-SY5Y and U-87 cells, was performed from
oligo(dT)17 primers using RevertAid Reverse Transcriptase
(Fermentas). The composition of the 5′-ends of the isoform--
specific cDNAs was analyzed by PCRs in the presence of
primer pair 5′-GGGGCGCTCTGGGTGTTGTA (exon 1) and
5′-CATGAAGTAGTGACAGATGGTTGG (exon 8). Prepara-
tions of cDNA from murine brain tissue and NIH-3 T3 cells
were subject to PCR analysis using primer pair 5′-AGAG-
CAGTCGGTGACAGTCC (exon 1) and 5′-CGAAAAACAC-
GATATCAGGCTTTAC (exon 10/11 transition).
Amplification of the full-length ORFs of human SIRT2
isoforms by nested-PCRs was performed using primer
pair 5′-GCCCTTTACCAACATGGCTGC (exon 1) and
5′-GTCTCCAATAAGCAATGTCTTCTG (exon 16) in prima-
ry PCRs. Gel-purified products were used as template in
secondary PCRs. The isoform 5-specific 5′-fragment was
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amplified using primer pair 5 ′-GGGGCGCTCTG
GGTGTTGTA (exon 1) and 5′-CAGATGACTCTGCCA
CGGTC (exon 1/5 transition). The isoform 5-specific
3′-fragment was amplified using primer pair 5′-CATGGCA
GAGCCAGACCGTC (exon 1/5 transition) and 5′-CTGC
TGGTTAAGAGGGGGCC (exon 16). Full-length SIRT2
ORFs were amplified using a non-discriminating primer
pair 5′-GGGGCGCTCTGGGTGTTGTA (exon 1) and
5′-CTGCTGGTTAAGAGGGGGCC (exon 16).
Vector construction
The ORFs of the SIRT2 isoforms were amplified from
293 cDNA using forward primer 5′-agttaagcttgccacc
ATGGCAGAGCCAGACCG (isoforms 1 and 5) and 5′-agt
taagcttgccaccATGGACTTCCTGCGGAAC (isoform 2)
along with reverse primer 5′-atcgtctagaacaCTGGGGT
TTCTCCCTCTC and ligated into eukaryotic expression
vector pcDNA3.1/V5-His (Invitrogen/Life Technologies)
via HindIII and XbaI sites.
For prokaryotic expression of the SIRT2 isoforms, the
encoding ORFs were amplified from the corresponding
eukaryotic vectors using forward primer 5′-gcatccATGGCA
GAGCCAGACCCCTCTCACCC (isoform 1), 5′-cgtgccATG
GACTTCCTGCGGAACTTATTC (isoform 2) and 5′-gcatcc
ATGGCAGAGCCAGACCGTCGCAGAG (isoform 5) along
with reverseprimer 5′-ggacggatccTCAATGGTGATGGTGAT
GATGACC. The DNA fragments were ligated into pET9d
(Novagen) via NcoI and BamHI sites.
Mutation of the base triplet encoding the catalytic histidine
(i.e., H187 in isoform1) into a tyrosine codonand themutation
of the second ATG triplet in the ORF of isoform 1 into an
alanine codon was performed by PCR-based site-directed
mutagenesis.
For prokaryotic expression of the acetyltransferase domain
of p300 (HATc), the encodingORF (spanning residues1284–
1845) was subcloned from a pT7T vector containing the
human p300 cDNA (pT7Ts-p300 [51])§ by PCR amplification
using forward primer 5′-gcgaattcagcggccgcAAAGAAAA
TAAGTTTTCTGCT and reverse primer 5′- gcgtacgtcgac
CCTGTTGCTGCCCAACCACACC. The DNA fragment was
ligated into pSXG [52] via EcoRI and SalI restriction sites.
For expression of the SIRT2 isoforms in the context of
their endogenous 5′-UTRs, isoform-specific 5′-UTRs were
amplified from 293 cDNA using forward primer 5′-ctcgtttagt
gaaAGAGTATTCGGGAGGACTACAACTCTC along with
reverse primer 5′-GCGCGGTGCTGAAGCCC. The result-
ing PCR products were fused to the downstream ORFs and
subsequently inserted into pFLAG-CMV4 via EcoICRI and
BamHI sites.
Mutation of the base triplet encoding the start codon of
isoform 1 into a non-transcription initiating AAG triplet was
performed by PCR-based site-directed mutagenesis.
Immunocytochemistry and fluorescence microscopy
HeLa S3 cells grown on cover slips were fixed 24 h post
transfection with 4% formaldehyde in PBS, permeabilized
with 0.5% Triton X-100 in PBS and blocked for 1 h at room
temperature using complete culture medium. Cells were
incubatedwith primary antibodies overnight at 4 °C, washed
twice with PBS and once with PBS containing 0.1% (v/v)
Triton X-100 prior to adding secondary antibodies. Following
1 h incubation at room temperature, chromatin was stained
with 4′,6-diamidino-2-phenylindole and cells were subjected
to fluorescencemicroscopy. Imageswere acquired using an
inverted Leica DMI 6000B fluorescence microscope
equipped with a 100× oil immersion objective (numerical
aperture, 1.4).
Cell fractionation
293 cells were grown in 60 mm dishes and transfected
with SIRT2 encoding vectors. Twenty-four hours after
transfection, cells were trypsinized and resuspended in
DMEM medium. Cells were centrifuged (900 rpm, 5 min)
andwashed oncewithPBS.Nuclear extractswere prepared
as described earlier [53] with following modifications: The
supernatant, after NP-40 addition, was collected as cyto-
plasmic fraction and not further processed. Genomic DNA
was removed by adding 2 units DNase I (Promega), 5 mM
MgCl2 and 5 mM CaCl2 to the nuclear pellet followed by
20 min incubation at 37 °C. Fractions were subject to
immunoblot analyses.
Protein expression and purification
Recombinant proteins were expressed inEscherichia coli
strain BL21(DE3)-CodonPlus cells (Stratagene) grown in 2×
YTG medium supplemented with appropriate antibiotics.
Expression was induced at OD600nm of 0.6 with 300 μM
IPTG and 5 μM zinc acetate and conducted overnight at
18 °C.
Recombinant SIRT2 isoforms were purified by Ni2+-NTA
chromatography (Qiagen) according to the manufacturer's
protocol using the following buffers: All buffer contained
50 mM Tris–HCl (pH 7.6) and 500 mM NaCl; additionally,
the lysis/binding buffer contained 5 mM imidazole, the first
washing buffer contained 20 mM imidazole, the second
washing buffer contained 50 mM imidazole and the elution
buffer contained 500 mM imidazole.
Recombinant GST and p300-HATs were affinity purified
as described earlier [52].
All proteins were dialyzed (10,000 molecular weight cutoff)
against deacetylation buffer [50 mM Tris–HCl (pH 7.6),
137 mM NaCl, 2.7 mM KCl and 10 mM MgCl2] supplement-
ed with 0.5 mM DTT.
Deacetylation assays
Deacetylation activity of recombinant SIRT2 isoforms
was assayed using four different approaches.
The deacetylation activity of purified SIRT2 isoforms
was measured using the CycLex SIRT2 Deacetylation
Fluorometric Assay Kit (MBL International). Reactions were
performed with 0.8 μM SIRT2 according to the manufac-
turer's protocol. All given values were blank corrected.
The deacetylation activity of purified SIRT2 isoforms
toward specific targets was carried out in deacetylation
buffer using 1 mM purified SIRT2, 1 mMNAD+ and 0.4 mM
target protein. Reactions were incubated at 30 °C for 2 h.
Control samples were incubated in the presence of 20 mM
nicotinamide (Nam). The reactions were terminated with
SDS sample buffer and the acetylation state of target
proteins was monitored by immunoblot analyses.
The deacetylation activity of SIRT2 isoforms in soluble
fractions of lysates from bacteria expressing theses proteins
1688 Nuclear Localization of a Sirtuin-2 Isoform
was carried out as described above with the following
modification: The amount of the SIRT2 isoforms in the
lysates was quantified by immunoblot analysis. Subse-
quently, the SIRT2 content in the bacterial lysates was
adjusted by dilution with lysate from bacteria harboring the
“empty” vector. Cell extracts containing a total of 20 μg
protein were mixed with 20 μg of lysates from bacteria
expressing p300-HATc or 5 μg of chemically acetylated
histones||.
In living bacteria, the deacetylation activity of the three
SIRT2 isoforms was monitored by co-expression with
p300-HATc in E. coli. Bacteria were transformed with
equimolar amounts of expression vectors and grown on
agar plates in the presence of appropriate antibiotics. One
colony was transferred into 15 ml of 2× YTG medium and
expressionwas inducedas describedabove. Subsequently,
the bacteria were grown overnight at 18 °C. The OD600nm of
the cultures was determined and cells were harvested by
centrifugation. Cells were lysed with SDS sample buffer and
equal protein amounts (estimated by OD600nm value) were
subjected to immunoblot analyses.
SIRT2-p300 interaction assay
Proteins were purified as described above and dialyzed
overnight against HAT buffer [50 mM Tris–HCl (pH 8),
137 mM NaCl, 2.7 mM KCl, 0.5 mM DTT and 10% (v/v)
glycerol]. Protein concentrations were determined using
BCA protein assay kit (Pierce). Proteins were mixed and
diluted to reach 1:5 molar ratio (p300/GST:SIRT2).
Acetyl-CoA, NAD+ or buffer was added as indicated and
samples were incubated at 30 °C for 2 h, followed by
overnight incubation at 4 °C. Pulldown was performed by
incubating samples with glutathione Sepharose in washing
buffer [50 mMTris–HCl (pH 8), 200 mMNaCl and 0.1% (v/v)
NP-40] for 1 h at 4 °C. Samples were subsequently washed
four timeswith washing buffer and oncewith 50 mMTris–HCl
(pH 8). Bound proteins were detected by immunoblot
analyses.
Protein stability measurement
Bacterially expressed SIRT2 isoforms were purified
by Ni2+-NTA chromatography as described above and
were eluted with low ionic strength elution buffer [50 mM
Tris–HCl (pH 8), 50 mM NaCl and 500 mM imidazole].
Samples were diluted 1:2 with ion-exchange buffer A
[50 mMTris–HCl (pH 8)] and subjected to anion-exchange
chromatography using MonoQ 5/50 column (GE Health-
care) on an automated ÄKTA purifier system (Amersham
Bioscience) with a linear gradient from buffer A to buffer B
(buffer A containing 1 M NaCl). Subsequently, the proteins
were dialyzed overnight against denaturation buffer
[50 mM Tris–HCl (pH 8) and 250 mM NaCl].
Samples were adjusted to indicate final concentrations of
GdmCl by dilution with 8 M GdmCl in denaturation buffer
and incubated for 1 h at 25 °C prior tomeasuring tryptophan
fluorescence. Emission spectra were recorded from 300 to
400 nm (5 nm bandwidth) at 25 °C after excitation at
290 nm (5 nm bandwidth) using a LS 50B fluorescence
spectrometer (PerkinElmer). Datawere blank corrected and
the ratios of the fluorescence intensities at 330 and 360 nm
calculated.
Protein structure prediction
Structural models of SIRT2 isoforms 1 and 5 were
generated using the Web-based homology and threading
server Swiss-Model (automated mode) [54–56], HHpred/
MODELLER (best template mode) [57–60], M4T Server
Version 3.0 [61,62], I-Tasser (restrain-free) [63,64] and
RaptorX (multiple template refraining) [65]. Manual
model–structure comparison and generation of electro-
static surface potential maps were performed using the
PyMOL Molecular Graphics System, Version 1.3 Schrö-
dinger, LLC.
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Supplementary Material 
 
Figures S1 SIRT2 isoform 5 is composed of exon 1 and exons 5-16. Nested PCR analysis of cDNAs 
derived from 293 and SH-SY5Y cells. The exon composition and length of the amplified DNA 
fragments is shown below the agarose gels, triangles indicate the location of primer sequences. The 
size of selected marker bands (bp) is indicated. The major product of the primary reactions is a ~2000 
bp fragment. Secondary PCRs were carried out with gel purified primary PCR products using three 
different primer pairs: (i) for isoform 5- specific amplification of the 5’ region, (ii) for isoform 5-
specific amplification of the 3’ region, and (iii) for non-discriminative amplification of all SIRT2 
cDNAs. Reactions (i) and (ii) resulted in a specific amplicon that originated from a splice event 
linking exon 1 and exons 5-16 as revealed by DNA sequence analysis. Reaction (iii) resulted in the 
amplification of three specific products corresponding to isoforms 1, 2, and 5 as revealed by DNA 
sequence analyses. 
 
Figures S2 Multiple sequence alignment of SIRT2 isoforms. Isoform 2 is a truncated form of isoform 
1 lacking the first 37 residues, whereas in isoform 5 residues 6-76 are substituted for an arginine. The 
structurally resolved residues of isoform 1 are highlighted in blue. The NES within the N-terminal 
region is indicated in red, the NLS predicted by cNLS mapper in violet, α-helices in orange and β-
sheets in grayblue. The catalytic domain as defined by multiple sequence alignment and structural 
data is framed: the black frame indicates the Rossmann-fold and the gray frame the small zinc-
 
containing subdomain. Residues involved in cosubstrate binding and catalytic mechanism are 
indicated by (#), zinc- coordinating cysteine by (◊), and tryptophans by (‡). 
 
Figures S3 Structural models of SIRT2 isoform 5 are similar to the solved structure. (a) Summary of 
the obtained models and comparison of their structural divergence to the solved structure (pdb: 3zgo). 
(b) Overlay of SIRT2 structure and isoform 5 models in ribbon representation. The positions of α-
helices α0, α1 (red) and α15 are indicated. Note, that the loop between α0 and α1 is not resolved in the 
structure (purple line; upper panel). Both α0 and α1 are not present in isoform 5. Secondary structure 
elements are colored: α-helices in bluegray, β-sheets in orange, and loop regions in black. The 
coordinated zinc atom is displayed in dark red and the catalytic histidine (H187, isoform 1) in stick 
representation. The C- and N-termini (Ni1: isoform 1, Ni5: isoform 5) are indicated. All obtained 
models adopt the SIRT2 catalytic domain structure and display most structural conservation within 
the secondary structure elements as well as most divergence within the loop regions. 
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